

## ***CURRICULUM VITAE***

### **Edoardo G. Giannini**

Professore Ordinario di Gastroenterologia dell'Università degli Studi di Genova. Dipartimento di Medicina Interna, Università degli Studi di Genova. IRCCS Ospedale Policlinico San Martino, Genova.

*Genova, 1 novembre 2020*

*"Ai sensi e per effetto del Regolamento (UE) 2016/679 DEL PARLAMENTO EUROPEO E DEL CONSIGLIO del 27 aprile 2016 relativo alla protezione delle persone fisiche con riguardo al trattamento dei dati personali, autorizzo al trattamento dei dati e delle informazioni contenute nel curriculum vitae ai fini del procedimento ECM, consapevole che il CV verrà incluso nell'allegato all'atto della validazione della richiesta di accreditamento, e che sarà visibile nella Banca Dati del sito ECM, accessibile a tutti gli utenti e tramite INTERNET (motori di ricerca). Autorizzo altresì il trattamento ai fini della trasmissione (successiva allo svolgimento dell'evento formativo) alla Commissione Nazionale per la Formazione Continua"*

## **Dati personali:**

Nome: Edoardo Giovanni Battista Giannini.  
Cittadinanza: Italiana.  
Data di nascita (luogo): 4 settembre 1970 (Genova, Italia).  
Indirizzo di lavoro: Cattedra di Gastroenterologia,  
Dipartimento di Medicina Interna,  
Università degli Studi di Genova.  
Viale Benedetto XV, 6  
16132 – Genova,  
Italia

## **Istruzione:**

- 1988 Diploma di maturità scientifica** presso l'Istituto dei Padri Maristi "Marcellino Champagnat" di Genova.
- 1995 Laurea in Medicina e Chirurgia** (Università degli Studi di Genova). Tesi: "Effetti della terapia con Interferone sulla formazione di monoethylglycinexylidide (MEGX) in pazienti con epatite cronica".
- 1999 Diploma di Specialista in Gastroenterologia ed Endoscopia Digestiva** (Scuola di Specializzazione in Gastroenterologia ed Endoscopia Digestiva dell'Università di Genova). Tesi "Effetti dell'eradicazione dell'*Helicobacter pylori* sull'Aminopirina breath test".
- 2004 Dottore di Ricerca in Gastroenterologia Clinica e Sperimentale** (Università degli Studi di Genova). Tesi: "Usi diagnostici dei <sup>13</sup>C-breath tests in pazienti affetti da epatopatia cronica".

## **Esperienza di ricerca e professionale:**

- 2004 Assegno per la collaborazione ad attività di ricerca.** Programma: "Studio dei fattori predittivi per la presenza di varici esofagee in pazienti con cirrosi epatica, ricerca dei parametri non-invasivi per la loro diagnosi, ed analisi del rapporto costo-beneficio dell'applicazione di tali parametri nello screening", settore scientifico-disciplinare MED/12 Gastroenterologia presso il Dipartimento di Medicina Interna e Specialità Mediche (DiMI), Università degli Studi di Genova.
- 2005 Ricercatore Universitario** settore scientifico-disciplinare MED/12 Gastroenterologia presso la Facoltà di Medicina e Chirurgia dell'Università di Genova e dalla medesima data presta servizio presso il Dipartimento di Medicina Interna e Specialità Mediche dell'Ateneo.

- 2006** Equiparazione a **Dirigente medico di I livello a tempo pieno**, in servizio presso l'Unità Operativa di Clinica Gastroenterologica con Endoscopia dell'Istituto di Ricovero e Cura a Carattere Scientifico-Azienda Ospedaliera Universitaria-IST San Martino di Genova.
- 2008** **Conferma nel ruolo di Ricercatore Universitario**, optando per il regime di impegno a tempo pieno.
- 2013** **Abilitazione Scientifica Nazionale (ASN):**
- **Prima Fascia** nel settore concorsuale 06/D4 (**Malattie Cutanee, Malattie Infettive e Malattie dell'Apparato Digerente**; ottenuta il 16 dicembre 2013)
  - **Seconda Fascia** nel settore concorsuale 06/D4 (**Malattie Cutanee, Malattie Infettive e Malattie dell'Apparato Digerente**; ottenuta il 16 dicembre 2013)
  - **Seconda Fascia** nel settore concorsuale 06/B1 (**Medicina Interna**; ottenuta il 23 dicembre 2013).
- 2014** **Professore Associato** per il settore scientifico disciplinare MED/12 Gastroenterologia, settore concorsuale 06/D4 Malattie Cutanee, Malattie Infettive e Malattie dell'Apparato Digerente, del Dipartimento di Medicina Interna dell'Università di Genova dopo essere risultato vincitore di procedura selettiva volta alla copertura di posti di professore di seconda fascia, mediante chiamata, ai sensi dell'art. 18, comma 1, della legge 30.12.2010, n. 240.
- 2017** **Professore Ordinario** per il settore scientifico disciplinare MED/12 Gastroenterologia, settore concorsuale 06/D4 Malattie Cutanee, Malattie Infettive e Malattie dell'Apparato Digerente, del Dipartimento di Medicina Interna dell'Università di Genova dopo essere risultato vincitore di procedura valutativa volta alla copertura di posti di professore di prima fascia, mediante chiamata, ai sensi dell'art. 24, comma 6, della legge 30.12.2010, n. 240.
- 2018** **Visiting Professor, Department of Internal Medicine, Digestive Diseases Section, Yale School of Medicine, Yale University (New Haven, CT, USA).**
- 2019** **Diploma di Formazione Manageriale** per Dirigenti di Struttura Complessa presso l'Accademia per il Management Sanitario (AMAS), Università degli Studi di Genova.
- 2020** **Direttore**, Scuola di Specializzazione in Malattie dell'Apparato Digerente dell'Università degli Studi di Genova.

## **Publicazioni scientifiche:**

Publicazioni su riviste internazionali con sistema di *peer-review*:

- **170 full papers,**
- **26 reviews,**
- **14 editoriali,**
- **10 case reports,**
- **56 lettere all'Editore,**
- **8 capitoli di libri.**
- **[ulteriori 6 full papers in cui risulta membro del gruppo collaborativo].**
  
- **Primo o ultimo autore in 172/276 (62%) pubblicazioni (257 dotate di Impact Factor).**

## **Indicatori bibliometrici (fonti: SCOPUS e Web of Science):**

- ***h-index*:** 44 (fonte: SCOPUS)
- **Numero totale delle citazioni:** 7,023 (fonte: SCOPUS)
- **"Impact Factor" totale :** 1,949.742 (fonte: Web of Science)
- **"Impact Factor" medio per pubblicazione:** 7.587 (fonte: Web of Science)

Classificato tra i "**Top Italian Scientists**", sezione **Clinical Sciences**

(<http://www.topitalianscientists.org>) da banca dati di analisi indipendente.

## **Attività didattica:**

### **CORSO DI LAUREA IN MEDICINA E CHIRURGIA**

#### ***Anni Accademici 2000/2001 - 2002/2003***

Attività di supporto alla didattica per la disciplina "Gastroenterologia" nel Corso Integrato di Malattie dell'Apparato Digerente.

#### ***Anni Accademici 2005/2006 - 2013/2014***

Attribuzione dell'insegnamento di "Gastroenterologia" (Professore Aggregato) del Corso Integrato di "Patologia Integrata Medico Chirurgica Apparato Gastroenterico".

#### ***Anni Accademici 2014/2015 – 2017/2018***

Docente del Corso Integrato di "Patologia Integrata Medico Chirurgica Apparato Gastroenterico".

#### ***Anni Accademici 2018/2019 –***

Titolare del Corso Integrato di "Malattie dell'Apparato Digerente".

### **CORSO DI LAUREA IN SCIENZE INFERMIERISTICHE**

#### ***Anni Accademici 2006/2007 – 2009/2010***

Attribuzione dell'insegnamento di "Gastroenterologia" (Professore Aggregato) del Corso Integrato di "Infermieristica Clinica in Medicina e Chirurgia Specialistica".

### **CORSO DI LAUREA IN INFERMIERISTICA PEDIATRICA**

#### ***Anni Accademici 2013/2014 –***

Docente dell'insegnamento di Gastroenterologia del Corso Integrato di "Infermieristica Clinica nei problemi prioritari di salute".

### **CORSO DI LAUREA IN FISIOTERAPIA**

#### ***Anni Accademici 2013/2014***

Attribuzione modulo disciplinare di "Gastroenterologia" (Professore Aggregato) del Corso Integrato di "Medicina Generale e Specialistica Applicata alla Riabilitazione".

### **SCUOLA DI SPECIALIZZAZIONE IN GASTROENTEROLOGIA ED ENDOSCOPIA DIGESTIVA**

#### ***Anno Accademico 2000/2001***

Attività di supporto alla didattica per la disciplina "Gastroenterologia".

### ***Anni Accademici 2001/2002 - 2004/2005***

Contratto di prestazione d'opera intellettuale (articolo 32 dello Statuto dell'Università di Genova, "Professore a contratto") per lo svolgimento del corso di "Semeiotica Funzionale Epato-biliare", integrativo del corso ufficiale di "Clinica Gastroenterologica".

### **SCUOLA DI SPECIALIZZAZIONE IN GASTROENTEROLOGIA**

#### ***Anni Accademici 2005/2006 - 2007/2008***

Attribuzione dell'insegnamento di "Fisiopatologia Epatica".

#### ***Anni Accademici 2006/2007 -***

Attribuzione dell'insegnamento di "Gastroenterologia (Clinica delle Malattie Digestive III + Semeiotica Funzionale e Strumentale Gastroenterologica III)".

### **DOTTORATO DI RICERCA**

#### ***Cicli dal XXII (2007) al XXXII (2017)***

**Docente** del Corso di Dottorato in Medicina Interna, Autoimmunità e Malattie dell'Apparato Digerente afferente alla Scuola di Dottorato di Ricerca in Medicina Interna Clinico-Sperimentale avente sede amministrativa presso l'Università degli Studi di Genova.

**Membro effettivo del Comitato dei Docenti** della Scuola di Dottorato di Ricerca in Medicina Interna Clinico-Sperimentale avente sede amministrativa presso l'Università degli Studi di Genova (dal Ciclo XXII al Ciclo XXXII).

#### ***Ciclo dal XXXIII (2017) al XXXV (2022)***

**Coordinatore** del Corso di Dottorato in Emato-Oncologia e Medicina Interna Clinico-Traslazionale avente sede amministrativa presso l'Università degli Studi di Genova.

### **MASTER UNIVERSITARIO DI II LIVELLO**

#### ***Anni Accademici 2004/2005 - 2012/2013***

**Docente** del Master Universitario di II livello in Emostasi e Trombosi dell'Università degli Studi di Genova (dall'istituzione al termine del Master stesso avvenuto nell'AA 2012-13).

#### ***Anni Accademici 2018/2019***

**Docente** del Master Universitario di II livello per Biologo Nutrizionista esperto in approcci integrati per la salute umana dell'Università degli Studi di Genova.

## **Incarichi ricevuti in qualità di esperto da Istituzioni italiane:**

### **Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR):**

- **Valutatore** di Progetti di ricerca di Rilevante Interesse Nazionale “**PRIN 2012**”.
- **Valutatore** di Progetti di ricerca di Rilevante Interesse Nazionale “**PRIN 2015**”.
- **Revisore** nella valutazione di prodotti di ricerca conferiti alla Valutazione della Qualità della Ricerca - **VQR 2004-2010** (GEV 05).
- **Revisore** nella valutazione di prodotti di ricerca conferiti alla Valutazione della Qualità della Ricerca - **VQR 2004-2010** (GEV 06).
- **Revisore** nella valutazione di prodotti di ricerca conferiti alla Valutazione della Qualità della Ricerca - **VQR 2011-2014**.
- **Revisore** per il bando “**SIR 2014**”.
- **Componente GEV** (GEV 06) per la valutazione di prodotti di ricerca conferiti alla Valutazione della Qualità della Ricerca - **VQR 2015-2019**.
  
- **Delegato del Ministero della Salute** al World Hepatitis Summit 2017 della World Health Organization in qualità di relatore esperto sulla tematica infezione cronica da HCV.

### **Agenzia Italiana del Farmaco (AIFA):**

- **Revisore** di Progetti di Ricerca Indipendente, bando **2017**.

### **Università di Modena e Reggio Emilia:**

- **Revisore** per il finanziamento di progetti di ricerca su Fondi di Ateneo per la Ricerca **2014**.

### **Regione Lombardia**

- **Revisore** di progetti sottoposti al bando per il finanziamento della ricerca per contrastare l'emergenza da SARS-COV-2 (**2020**).



## **Incarichi ricevuti in qualità di esperto da Istituzioni estere:**

### **European Commission:**

- **Experts' Database for the Research Framework Programmes 6** (Sixth Research Framework Programme, FP6), **membro**.
- **Experts' Database for the Research Framework Programmes 7** (Seventh Research Framework Programme, FP7), **membro**.
- **'Personalizing health and care' call (Progetto HORIZON 2020-PHC-2014)**, **revisore** di progetti di ricerca Internazionale.

### **National Institute of Health (NIH/NDDK) USA:**

- **Revisore** di progetti di ricerca in ambito epatologico.

### **Research Grants Council (RGC) of Hong Kong:**

- **Revisore** di progetti di ricerca in ambito epatologico ed epato-oncologico.

### **Cancer Research United Kingdom:**

- **Revisore** di progetti di ricerca in ambito epato-oncologico.

### **Research Foundation Flanders, Belgio:**

- Fonds Wetenschappelijk Onderzoek - Vlaanderen, FWO, **revisore** in merito ad *applications* per Post-Doctoral Fellowship e Senior Clinical Investigator.

### **EEA Financial Mechanism 2014-2021, Iceland, The Principality of Liechtenstein, The Kingdom of Norway and The Government of Romania:**

- **Revisore** di progetti sottoposti alla Executive Agency for Higher Education, Research, Development and Innovation Funding. Collaborative Research Projects (CRPs) undertaken by researchers from Romania and EFTA States (Norway, Iceland and Liechtenstein).

### **McMaster University, Canada:**

- **Membro dei reviewers** del progetto McMaster Plus Project, Health Information Research Unit.

## **Incarichi di Ateneo:**

### **- Membro eletto:**

- **Giunta della Facoltà di Medicina e Chirurgia (2008-2010).**
- **Consiglio del Centro di Facoltà di Medicina e Chirurgia (2008-2010).**
- **Consiglio della Scuola di Scienze Mediche e Farmaceutiche (2015-2017; 2018-).**
- **Giunta del Dipartimento di Medicina Interna (2008-2010; 2015-2017; 2018-).**
- **Senato Accademico, Università degli Studi di Genova (2012-2013; 2013-2015).**

### **- Coordinatore**

- **XXXIII Corso di Dottorato in Emato-Oncologia e Medicina Interna Clinico-Traslazionale, (2017-2020).**
- **XXXIV Corso di Dottorato in Emato-Oncologia e Medicina Interna Clinico-Traslazionale, (2018-2021).**
- **XXXV Corso di Dottorato in Emato-Oncologia e Medicina Interna Clinico-Traslazionale, (2019-2022).**

## **Affiliazioni a Società Scientifiche italiane ed estere:**

- Associazione Italiana per lo Studio del Fegato (**AISF**), 1996-
- European Association for the Study of the Liver (**EASL**), 1999-
- Società Italiana di Gastroenterologia (**SIGE**), 2005-
- Fellow dell'American College of Gastroenterology (**ACG**), 2005-
- Collegio Nazionale dei Docenti di Gastroenterologia (**UNIGASTRO**), 2005-
- American Association for the Study of Liver Diseases (**AASLD**), 2012-
- Fellow della Fondazione Italiana per la Ricerca in Epatologia (**FIRE**), 2018 -

## **Incarichi in Società Scientifiche:**

- **Membro eletto del Comitato Coordinatore:**
  - Associazione Italiana per lo Studio del Fegato (**AISF**), (2015-2018).
- **Segretario Generale:**
  - Associazione Italiana per lo Studio del Fegato (**AISF**), (2016-2018).
- **Presidente del Comitato di Indirizzo:**
  - Fondazione Italiana per la Ricerca in Epatologia (**FIRE**) (2018-2019).
- **Presidente:**
  - Società Italiana di Gastroenterologia (**SIGE**), Sezione Regionale Liguria (2018-).
- **Membro del Consiglio di Amministrazione:**
  - Fondazione Italiana per la Ricerca in Epatologia (**FIRE**) (2019-).
- **Membro del Comitato Scientifico:**
  - Fondazione delle Malattie Digestive (**FMD**) (2019-).
- **Governor:**
  - American College of Gastroenterology (**ACG**) (2020-)

## **Reviewer per le seguenti riviste scientifiche:**

- Acta Haematologica
- Acta Gastro-enterologica Belgica
- Anti-Cancer Drugs
- Alimentary Pharmacology and Therapeutics
- American Journal of Epidemiology
- American Journal of Gastroenterology
- Annals of Internal Medicine
- Annals of Hepatology
- Biologics: Targets and Therapy
- BMC Gastroenterology
- British Journal of Haematology
- Canadian Medical Association Journal
- Canadian Journal of Gastroenterology and Hepatology
- Cancer Epidemiology, Biomarkers & Prevention
- Clinical and Experimental Immunology
- Clinics and Research in Gastroenterology and Hepatology
- Clinical and Applied Thrombosis/Hemostasis
- Clinical and Translational Gastroenterology
- Clinical Gastroenterology and Hepatology
- Clinical Infectious Diseases
- Digestive Diseases and Sciences
- Digestive and Liver Disease
- Drug Discovery Today
- Drugs
- European Journal of Cancer
- European Journal of Clinical Epidemiology
- European Journal of Clinical Investigation
- European Journal of Clinical Nutrition
- European Journal of Gastroenterology and Hepatology
- European Radiology
- Free Radical Research
- Gastroenterology
- Gut
- Helicobacter
- Hepatology
- Hepatology Communications
- Hepatology International
- Immunotherapy
- Internal and Emergency Medicine
- International Journal of Evidence-Based Healthcare
- Journal of Breath Research
- Journal of Clinical Gastroenterology
- Journal of Clinical Outcomes
- Journal of Experimental & Clinical Cancer Research
- Journal of Gastroenterology and Hepatology
- Journal of Gastrointestinal and Liver Diseases
- Journal of General Internal Medicine
- Journal of Hepatology
- Journal of Medical Economics
- Journal of Medical Virology
- Journal of Obesity
- Journal of Pharmacy and Pharmacology
- Journal of Thrombosis and Haemostasis
- Journal of Viral Hepatitis
- Liver Cancer
- Liver International
- Liver Transplantation
- Nutrition Research
- Oncology
- Pediatric Transplantation
- Phytotherapy Research
- Platelets
- Reumatismo
- Saudi Medical Journal
- Scandinavian Journal of Gastroenterology
- The Lancet
- The Lancet Oncology
- The Oncologist
- Therapeutic Advances in Medical Oncology
- Transplantation
- Tumor Biology
- Transplant International
- United European Gastroenterology Journal
- World Journal of Gastroenterology
- World Journal of Hematology
- World Journal of Hepatology

## **Cariche editoriali in riviste scientifiche Internazionali:**

### **- Editore Associato:**

- *Liver Cancer International* (2019-)
- *Digestive and Liver Disease* (2018-)
- *Clinical Case Reports* (2014-2017)

### **- Membro dell'Editorial Board:**

- *World Journal of Gastroenterology* (2004-2017)
- *Gastroenterology Research and Practice* (2009-)
- *Journal of Gastroenterology and Hepatology Research* (2011-)
- *World Journal of Hematology* (2011-2018)
- *Datasets Papers in Medicine – Hepatology* (2012-2017)
- *Hepatoma Research* (2014-2016)
- *World Journal of Hepatology* (2014-2017)
- *Journal of Liver and Clinical Research* (2014-)
- *Journal of Translational Internal Medicine* (2014-)
- *Cancers* (2019-)

## **Altri ruoli editoriali:**

- **Membro del Comitato Editoriale** del libro di testo del Collegio Nazionale Docenti di Gastroenterologia (UNIGASTRO), edizione 2010-2012.
- **Co-estensore** delle “Raccomandazioni dell’Associazione Italiana Studio Fegato per la gestione dell’Epatocarcinoma”.
- **Co-estensore** delle “Raccomandazioni multisocietarie Italiane (AISF, AIOM, IT-IHPBA, SIC, SIRM, SITO) per la gestione clinica integrata del paziente con epatocarcinoma”.
- **Reviewer** degli abstract sottoposti alla Riunione Annuale AISF (2013-2015; 2019-)
- **Reviewer** degli abstracts sottoposti all’EASL *International Liver Congress* (2014-2017; 2017-2020).
- **Reviewer** degli abstracts sottoposti al 26°Congresso Internazionale della *Transplantation Society* (2016).
- **Reviewer** degli abstracts sottoposti al *meeting* annuale della *Transplantation Society* (2016-2018)

## **Fondi e finanziamenti:**

- Nell'anno 2002 (Bando 2001), ha ricevuto un "Finanziamento a progetti di singoli e/o giovani ricercatori" dell'Università degli Studi di Genova.
- Nell'anno 2011 ha ricevuto un finanziamento per "Progetto di Ricerca di Ateneo" dell'Università degli Studi di Genova.
- Nell'anno 2013 ha ricevuto un finanziamento per "Progetto di Ricerca di Ateneo" dell'Università degli Studi di Genova.
- Nell'anno 2014 ha ricevuto un finanziamento per "Progetto di Ricerca di Ateneo" dell'Università degli Studi di Genova.
- Fa parte del gruppo di studio multicentrico Italian Liver Cancer (Ita.Li.Ca).
- Ha partecipato a studi multicentrici sotto l'egida dell'Associazione Italiana Studio Fegato (A.I.S.F.).
- Primary European Investigator per lo studio di fase III ELEVATE (ELtrombopag EValuated for its Ability to overcome Thrombocytopenia and Enable procedures; ClinicalTrials.gov number, NCT00678587).
- Primary Italian Investigator per lo studio di fase II SHELTER (A proof-of-concept Phase II study to evaluate efficacy, safety and pharmacokinetics of 4SC-201 and the treatment combination of Sorafenib plus 4SC-201 in patients with hepatocellular carcinoma exhibiting progressive disease under Sorafenib treatment).

## **Attività clinica assistenziale:**

- 2002** Il 15 marzo 2002 è stato chiamato, in seguito a pubblico concorso, ad assumere servizio in qualità di Dirigente Medico a tempo indeterminato presso l'Unità Operativa Complessa di Gastroenterologia dell'Ospedale Santa Corona di Pietra Ligure (SV), incarico declinato.
- 2006-2017** Medico responsabile corsia presso l'Unità Operativa Complessa di Clinica Gastroenterologica con Endoscopia del Dipartimento di Medicina Interna dell'Istituto di Ricovero e Cura a Carattere Scientifico-Azienda Ospedaliera Universitaria-IST San Martino di Genova.
- 2006-2018** Medico responsabile della struttura di Day-Hospital dell'Unità Operativa Complessa di Clinica Gastroenterologica con Endoscopia del Dipartimento di Medicina Interna dell'Istituto di Ricovero e Cura a Carattere Scientifico-Azienda Ospedaliera Universitaria-IST San Martino di Genova.
- 2018-2019** Responsabile dell'Unità Operativa Semplice "Malattie Infiammatorie dell'Apparato Digerente" dell'Istituto di Ricovero e Cura a Carattere Scientifico-Ospedale Policlinico San Martino di Genova.
- 2019-2020** Responsabile di programma denominato "Diagnosi e Terapia della Malattie Emergenti dell'Apparato Digerente" dell'Istituto di Ricovero e Cura a Carattere Scientifico-Ospedale Policlinico San Martino di Genova, assimilato a tutti gli effetti all'incarico di Direzione di Struttura Complessa.
- 2020-** Direttore, Unità Operativa Complessa Clinica Gastroenterologica dell'Istituto di Ricovero e Cura a Carattere Scientifico-Ospedale Policlinico San Martino di Genova.

## Elenco delle pubblicazioni scientifiche

(in estenso su riviste dotate di peer-review):

### Articoli

1. Testa R, Picciotto A, Cagliaris S, **Giannini E**, Campo N, Alvarez S, Arzani L, Celle G. Effects of Interferon therapy on monoethylglycinyloxide formation in patients with chronic active hepatitis C. *Gastroenterol Intern* 1996; 9: 71-76.
2. Testa R, Cagliaris S, Risso D, Arzani L, Campo N, Alvarez S, **Giannini E**, Lantieri PB, Celle G. Monoethylglycinyloxide formation measurement as a hepatic function test to assess severity of chronic liver disease. *Am J Gastroenterol* 1997; 92: 2268-2273.
3. Testa R, Campo N, Cagliaris S, Risso D, Alvarez S, Arzani L, **Giannini E**, Lantieri PB, Celle G. Lidocaine elimination and monoethylglycinyloxide formation in patients with chronic hepatitis or cirrhosis. *Hepato-Gastroenterol* 1998; 45: 154-159.
4. Testa R, Ghia M, Mattioli F, Borzone S, Cagliaris S, Mereto E, **Giannini E**, Risso D. Effects of reduced glutathione and n-acetylcysteine on lidocaine metabolism in cimetidine treated rats. *Fund Clin Pharmacol* 1998;12: 220-224.
5. **Giannini E**, Botta F, Cagliaris S, Fasoli A, Risso D, Ceppa P, Cresta E, Venturino V, Icardi GC, Lantieri PB, Celle G, Testa R. Chronic liver disease related to hepatitis C virus: age of patients seems to be the main determinant of severity independently of viral genotype. *Eur J Gastroenterol Hepatol* 1999; 11: 553-558.
6. Testa R, Valente U, Risso D, Cagliaris S, **Giannini E**, Fasoli A, Botta F, Dardano G, Lantieri PB, Celle G. Can MEGX test and serum bile acids improve prognostic ability of Child-Pugh's score in liver cirrhosis? *Eur J Gastroenterol Hepatol* 1999; 11: 559-563.
7. **Giannini E**, Botta F, Fasoli A, Ceppa P, Risso D, Lantieri PB, Celle G, Testa R. Progressive liver functional impairment is associated to an increase in the AST/ALT ratio. *Dig Dis Sci* 1999; 44: 1249-1253.
8. Testa R, **Giannini E**, Picciotto A, Risso D, Cagliaris S, Fasoli A, Lantieri PB, Icardi GC, Lapertosa G, Celle G. Probability of non-response during interferon therapy in patients with chronic hepatitis C. *Hepato-Gastroenterol* 1999; 46: 1928-1936.
9. **Giannini E**, Botta F, Cataldi A, Tenconi GL, Ceppa P, Barreca T, Testa R. Leptin levels in nonalcoholic steatohepatitis and chronic hepatitis C. *Hepato-Gastroenterol* 1999; 46: 2422-2425.
10. **Giannini E**, Ceppa P, Botta F, Fasoli A, Romagnoli P, Cresta E, Venturino V, Risso D, Celle G, Testa R. Steatosis and bile duct damage in chronic hepatitis C: distribution and relationships in a group of Northern Italian patients. *Liver* 1999; 19: 432-437.
11. Fasoli A, **Giannini E**, Botta F, Romagnoli P, Testa R. <sup>13</sup>CO<sub>2</sub> excretion in breath of normal subjects and cirrhotic patients after <sup>13</sup>C-Aminopyrine oral load. Comparison with MEGX test in functional differentiation between chronic hepatitis and liver cirrhosis. *Hepato-Gastroenterol* 2000; 47: 234-238.



12. Testa R, Franceschini R, **Giannini E**, Cataldi A, Botta F, Fasoli A, Tenerelli P, Rolandi E, Barreca T. Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis. *J Hepatol* 2000; 33: 33-37.
13. **Giannini E**, Risso D, Ceppa P, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, Lantieri PB, Testa R. Utility of alpha glutathione S-transferase assessment in chronic hepatitis C patients with near-normal alanine aminotransferase levels. *Clin Biochem* 2000; 33: 297-301.
14. Botta F, **Giannini E**, Fasoli A, Romagnoli P, Risso D, Testa R. The monoethylglycinexylidide test does not impair psychometric performance in patients with chronic hepatitis or cirrhosis. *Ther Drug Monit* 2000; 22: 371-374.
15. Testa R, **Giannini E**, Ceppa P, Botta F, Romagnoli P, Fasoli A, Risso D. Histological determinants of monoethylglycinexylidide formation in patients with chronic hepatitis C. *Ther Drug Monit* 2000; 22: 455-459.
16. **Giannini E**, Borro P, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, Testa , Risso D, Lantieri PB, Antonucci A, Boccato M, Milone S, Testa R. Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis. *Int J Biol Markers* 2000; 15: 226-230.
17. Cagliaris S, **Giannini E**, Dardano G, Mondello L, Valente U, Testa R. Tauroursodeoxycholic acid administration as adjuvant therapy in cirrhotic patients on transplantation waiting lists. *Hepato-Gastroenterol* 2000; 47: 1045-1047.
18. **Giannini E**, Romagnoli P, Fasoli A, Chiarbonello B, Malfatti F, Botta F, Risso D, Lantieri PB, Savarino V, Testa R. Influence of Helicobacter pylori eradication therapy on 13C-aminopyrine breath test. A comparison among Omeprazole, Lansoprazole, or Pantoprazole containing regimens. *Am J Gastroenterol* 2000; 95: 2762-2767.
19. **Giannini E**, Ceppa P, Botta F, Mastracci L, Romagnoli P, Comino I, Pasini A, Risso D, Lantieri PB, Icardi GC, Barreca T, Testa R. Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C. *Am J Gastroenterol* 2000; 95: 3211-3217.
20. **Giannini E**, Arzani L, Borro P, Botta F, Fasoli A, Risso D, Celle G, Testa R. Does surveillance for hepatocellular carcinoma in HCV cirrhotic patients improve treatment outcome mainly due to better clinical status at diagnosis? *Hepato-Gastroenterol* 2000; 47: 1395-1398.
21. **Giannini E**, Cagliaris S, Ceppa P, Risso D, Lantieri PB, Testa R. Serum procollagen III peptide levels are related to lobular necrosis in untreated patients with chronic hepatitis C. *Eur J Gastroenterol Hepatol* 2001; 13: 137-141.
22. **Giannini E**, Botta F, Fasoli A, Romagnoli P, Mastracci L, Ceppa P, Comino I, Pasini A, Risso D, Testa R. Increased levels of  $\gamma$ GT suggest the presence of bile duct lesions in patients with chronic hepatitis C. Absence of influence of HCV genotype, HCV-RNA serum levels, and HGV infection on this histological damage. *Dig Dis Sci* 2001; 46: 524-529.
23. **Giannini E**, Fasoli A, Botta F, Testa E, Romagnoli P, Ceppa P, Testa R. Long-term follow-up of chronic hepatitis C patients after interferon treatment: a functional study. *J Gastroenterol Hepatol* 2001; 16: 399-405.
24. **Giannini E**, Mastracci L, Botta F, Romagnoli P, Fasoli A, Risso D, Faravelli F, Ceppa P, Lantieri PB, Icardi GC, Testa R. Liver iron accumulation in chronic hepatitis C patients without HFE

mutations: relationships with histological damage, viral load and genotype, and alpha glutathione S-transferase levels. *Eur J Gastroenterol Hepatol* 2001; 13: 1355-1361.

25. **Giannini E**, Fasoli A, Borro P, Chiarbonello B, Malfatti F, Romagnoli P, Botta F, Testa E, Fumagalli A, Polegato S, Savarino V, Testa R. Impairment of cytochrome P-450 dependent liver activity in cirrhotic patients with Helicobacter pylori infection. *Aliment Pharmacol Ther* 2001; 15: 1967-1973.
26. **Giannini E**, Fasoli A, Chiarbonello B, Malfatti F, Romagnoli P, Botta F, Testa E, Polegato S, Fumagalli A, Testa R. 13C-Aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. *Aliment Pharmacol Ther* 2002; 16: 717-725.
27. **Giannini E**, Fasoli A, Romagnoli P, Botta F, Fumagalli A, Polegato S, Sola S, Ceppa P, Testa R. Monitoring of liver metabolic function during interferon alpha therapy and its relationship to treatment outcome in chronic hepatitis C patients. *Hepato-Gastroenterol* 2002; 49: 778-782.
28. **Giannini E**, Borro P, Botta F, Fumagalli A, Malfatti F, Podestà E, Romagnoli P, Testa E, Chiarbonello B, Polegato S, Mamone M, Testa R. Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. *J Hepatol* 2002; 37: 572-577.
29. **Giannini E**, Botta F, Testa E, Romagnoli P, Polegato S, Malfatti F, Fumagalli A, Chiarbonello B, Risso D, Testa R. The 1-year and 3-month prognostic utility of the AST/ALT ratio and model for end-stage liver disease score in patients with viral liver cirrhosis. *Am J Gastroenterol* 2002; 97: 2855-2860.
30. **Giannini E**, Romagnoli P, Fasoli A, Botta F, Risso D, Testa R. Influence of age on clinical presentation, therapeutic options, and prognosis in anti-HCV positive cirrhotic patients with hepatocellular carcinoma. *Age Ageing* 2002; 31: 457-462.
31. Icardi G, Bruzzone B, Gota F, Torre F, **Giannini E**, Massone L, Li Bassi A, Lai PL, Picciotto A, Ansaldi F. A new assay for hepatitis C virus (HCV) core antigen detection: an alternative to nucleic acid technologies in positive or indeterminate anti-HCV subjects? *Ann Iggiene* 2003; 15: 863-870.
32. Botta F, **Giannini E\***, Romagnoli P, Fasoli A, Malfatti F, Chiarbonello B, Testa E, Risso D, Colla G, Testa R. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. *Gut* 2003; 52: 134-139. **\*I primi due autori condividono l'authorship dell'articolo.**
33. **Giannini E**, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, Testa E, Ceppa P, Testa R. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. *Arch Intern Med* 2003; 163: 218-224.
34. **Giannini E**, Ceppa P, Botta F, Fasoli A, Romagnoli P, Ansaldi F, Durando P, Risso D, Lantieri PB, Icardi GC, Testa R. Previous hepatitis B virus infection is associated to worse disease stage, and occult hepatitis B virus infection has low prevalence and pathogenicity in hepatitis C virus positive patients. *Liver Int* 2003; 23: 12-18.
35. **Giannini E**, Fasoli A, Botta F, Romagnoli P, Malfatti F, Chiarbonello B, Mamone M, Savarino V, Testa R. Helicobacter pylori infection is associated with greater impairment of cytochrome

P-450 liver metabolic activity in anti-HCV positive cirrhotic patients. *Dig Dis Sci* 2003; 48: 802-808.

36. Testa R, Testa E, **Giannini E**, Botta F, Malfatti F, Chiarbonello B, Fumagalli A, Polegato S, Podestà E, Romagnoli P, Risso D, Cittadini G, De Caro G. Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment. *Aliment Pharmacol Ther* 2003; 15: 1563-1569.
37. **Giannini EG**, Botta F, Borro P, Risso D, Romagnoli P, Fasoli A, Mele MR, Testa E, Mansi C, Savarino V, Testa R. Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis. *Gut* 2003; 52: 1200-1205.
38. **Giannini E**, Botta F, Borro P, Malfatti F, Fumagalli A, Testa E, Podestà E, Chiarbonello B, Polegato S, Mamone M, Testa R. Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection. *Am J Gastroenterol* 2003; 98: 2516-2520.
39. **Giannini E**, Romagnoli P, Tenconi GL, Botta F, Malfatti F, Chiarbonello B, Mamone M, Barreca T, Testa R. High ascitic fluid leptin levels in patients with decompensated liver cirrhosis and sterile ascites: relationship with TNF- $\alpha$  levels. *Dig Dis Sci* 2004; 49: 275-280.
40. **Giannini E**, Botta F, Fumagalli A, Malfatti F, Testa E, Chiarbonello B, Polegato S, Bellotti M, Milazzo S, Borgonovo G, Testa R. Can inclusion of serum creatinine values improve the Child-Turcotte-Pugh score and challenge the prognostic yield of the model for end-stage liver disease score in the short-term prognostic assessment of cirrhotic patients? *Liver Int* 2004; 24: 465-470.
41. **Giannini E**, Risso D, Botta F, Romagnoli P, Malfatti F, Fumagalli A, Testa E, Podestà E, Chiarbonello B, Polegato S, Testa R. Prognosis of hepatocellular carcinoma in anti-HCV positive cirrhotic patients. A single-centre comparison among four different staging systems. *J Intern Med* 2004; 255: 399-408.
42. Malfatti F, **Giannini E**, Emanuela T, Polegato S, Podestà E, Fumagalli A, Cotelessa T, Chiarbonello B, Bellotti M, Botta F, Milazzo S, Testa R. Effects of the association of lansoprazole, clarithromycin and metronidazole for *Helicobacter pylori* eradication therapy, measured by the  $^{13}\text{C}$  Aminopyrine breath test. *Med Sci Monit* 2005; 11: PI 14-18.
43. **Giannini EG**, Fasoli A, Borro P, Botta F, Malfatti F, Fumagalli A, Testa E, Polegato S, Cotellessa T, Milazzo S, Risso D, Testa R.  $^{13}\text{C}$ -Galactose breath test and  $^{13}\text{C}$ -Aminopyrine breath test for the study of liver function in chronic liver disease. *Clin Gastroenterol Hepatol* 2005; 3: 279-285.
44. **Giannini EG**, Malfatti F, Botta F, Polegato S, Testa E, Fumagalli A, Mamone M, Savarino V, Testa R. Influence of one-week *Helicobacter pylori* eradication therapy with rabeprazole, clarithromycin, and metronidazole on  $^{13}\text{C}$ -Aminopyrine breath test. *Dig Dis Sci* 2005; 50: 1207-1213.
45. **Giannini EG**, Botta F, Borro P, Dulbecco P, Testa E, Mansi C, Savarino V, Testa R. Application of the platelet count/spleen diameter ratio to rule out the presence of oesophageal varices in patients with cirrhosis: A validation study based on follow-up. *Dig Liver Dis* 2005; 37: 779-785.

46. **Giannini EG**, Risso D, Caglieris S, Testa R. Longitudinal modifications of the MELD score have prognostic meaning in patients with liver cirrhosis. *J Clin Gastroenterol* 2005; 39: 912-914.
47. **Giannini EG**, Bilardi C, Dulbecco P, Mamone M, Santi ML, Testa R, Mansi C, Savarino V. A study of four- and seven-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole in patients with treatment-resistant *Helicobacter pylori* infection. *Aliment Pharmacol Ther* 2006; 23: 281-287.
48. Testa E, Malfatti F, Milazzo S, Cordiviola C, Cotellessa T, Marabotto E, **Giannini E**, Ceppa P, Mamone M, Risso D, Testa R. Hyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver disease. *Liver Int* 2006; 26: 439-444.
49. **Giannini EG**, Bilardi C, Dulbecco P, Mamone M, Santi ML, Testa R, Mansi C, Savarino V. Can *Helicobacter pylori* eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of four- and seven-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole. *J Clin Gastroenterol* 2006; 40: 515-520.
50. **Giannini EG**, Zaman A, Ceppa P, Mastracci L, Risso D, Testa R. A simple approach to non-invasively identifying significant fibrosis in chronic hepatitis C patients in clinical practice. *J Clin Gastroenterol* 2006; 40: 521-527.
51. Testa R, Testa E, **Giannini E**, Borro P, Milazzo S, Isola L, Ceppa P, Lantieri PB, Risso D. Noninvasive ratio indexes to evaluate fibrosis staging in chronic hepatitis C: role of platelet count/spleen diameter ratio index. *J Intern Med* 2006; 260: 142-150.
52. **Giannini EG**, Savarino V, Testa R. Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastro-oesophageal reflux disease. *Dig Dis Sci* 2006; 51: 1602-1606.
53. **Giannini EG**, Zentilin P, Dulbecco P, Iiritano E, Bilardi C, Savarino E, Mansi C, Savarino V. A comparison between sodium alginate and magaldrate anhydrous in the treatment of patients with gastroesophageal reflux symptoms. *Dig Dis Sci* 2006; 51: 1904-1909.
54. **Giannini EG**, Zaman A, Kreil A, Floreani A, Dulbecco P, Testa E, Sohaey R, Verhey P, Peck-Radosavljevic M, Mansi C, Savarino V, Testa R. Platelet count/spleen diameter ratio for the non invasive diagnosis of esophageal varices. Results of a multi-center, prospective, validation study. *Am J Gastroenterol* 2006; 101: 2511-2519.
55. **Giannini EG**, Risso D, Testa R, Trevisani F, Di Nolfo MA, Del Poggio P, Benvegnù L, Ludovico Rapaccini G, Farinati F, Zoli M, Borzio F, Caturelli E; Italian Liver Cancer (ITA.LI.CA.) Group. Prevalence and prognostic meaning of the presence of oesophageal varices in patients with hepatocellular carcinoma. *Clin Gastroenterol Hepatol* 2006; 4: 1378-1384.
56. Trevisani F, Magini G, Santi V, Morselli-Labate AM, Cantarini MC, Di Nolfo MA, Del Poggio P, Benvegnù L, Rapaccini G, Farinati F, Zoli M, Borzio F, **Giannini EG**, Caturelli E, Bernardi M; Italian Liver Cancer (ITA.LI.CA) Group. Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. *Am J Gastroenterol* 2007; 102: 1022-1031.
57. Burton JR Jr, Liangpunsakul S, Lapidus J, **Giannini E**, Chalasani N, Zaman A. Validation of a multivariate model predicting presence and size of varices. *J Clin Gastroenterol* 2007; 41: 609-615.

58. Trevisani F, Santi V, Gramenzi A, Di Nolfo MA, Del Poggio P, Benvegnù L, Rapaccini G, Farinati F, Zoli M, Borzio F, **Giannini EG**, Caturelli E, Bernardi M; Italian Liver Cancer Group. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis? *Am J Gastroenterol* 2007; 102: 2448-2457.
59. **Giannini EG**, Zentilin P, Dulbecco P, Vigneri S, Scarlata P, Savarino V. Management strategy for patients with gastroesophageal reflux disease: a comparison between empirical treatment with esomeprazole and endoscopy-oriented treatment. *Am J Gastroenterol* 2008; 103: 267-275.
60. Farinati F, Sergio A, Baldan A, Giacomini A, Di Nolfo MA, Del Poggio P, Benvegnù L, Rapaccini G, Zoli M, Borzio F, **Giannini EG**, Caturelli E, Trevisani F. Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study. *BMC Cancer* 2009, 9:33.
61. Agha A, Anwar E, Bashir K, Savarino V, **Giannini EG**. External validation of the platelet count/spleen diameter ratio for the diagnosis of oesophageal varices in hepatitis C virus-related cirrhosis. *Dig Dis Sci* 2009; 54: 654-660.
62. Basso M, **Giannini EG\***, Torre F, Bianchi S, Savarino V, Picciotto A. Elevations in ALT levels late the course of antiviral therapy in HCV-RNA negative patients are associated with virological relapse. *Hepatology* 2009; 49: 1442-1448. **\*I primi due autori condividono l'authorship dell'articolo.**
63. **Giannini EG**, Marabotto E, Savarino V, Trevisani F, di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M; Italian Liver Cancer (ITALICA) Group. Hepatocellular carcinoma in patients with cryptogenic cirrhosis. *Clin Gastroenterol Hepatol* 2009; 7: 580-585.
64. Farinati F, Sergio A, Giacomini A, Di Nolfo MA, Del Poggio P, Benvegnù L, Rapaccini G, Zoli M, Borzio F, **Giannini EG**, Caturelli E, Trevisani F; Italian Liver Cancer group. Is female gender a significant favourable prognostic factor in hepatocellular carcinoma (HCC)? *Eur J Gastroenterol Hepatol* 2009; 21: 1212-1218.
65. Torre F, Basso M, **Giannini EG**, Feasi M, Boni S, Grasso A, De Leo P, Dodi F, Marazzi MG, Azzola E, Bartolacci V, Percario G, Beltrame A, Borro P, Picciotto A; Ligurian HBV Study Group. Clinical and virological survey of patients with hepatitis B surface antigen in an Italian region: clinical considerations and disease burden. *J Med Virology* 2009; 81: 1882-1886.
66. Parodi A, Dulbecco P, Savarino V, **Giannini EG**, Bodini G, Corbo M, Isola L, De Conca S, Marabotto E, Savarino V. Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared to controls with similar age and gender distribution. *J Clin Gastroenterol* 2009; 43: 962-966.
67. **Giannini EG**, Torre F, Basso M, Feasi M, Boni S, Grasso A, De Leo P, Dodi F, Marazzi MG, Azzola E, Bartolacci V, Percario G, Beltrame A, Borro P, Savarino V, Picciotto A; Ligurian Hepatitis B Virus Study Group. A significant proportion of patients with chronic hepatitis B who are candidates for antiviral treatment are untreated: a region-wide survey in Italy. *J Clin Gastroenterol* 2009; 43: 1001-1007.

68. **Giannini EG**, Basso M, Savarino V, Picciotto A. Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension. *J Intern Med* 2009; 266: 537-546.
69. **Giannini EG**, Bodini G, Corbo M, Savarino V, Risso D, Di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA.) group. Impact of evidence-based medicine on treatment of patients with unresectable hepatocellular carcinoma. *Aliment Pharmacol Ther* 2010; 31: 493-501.
70. **Giannini EG**, Basso M, Savarino V, Picciotto A. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. *Aliment Pharmacol Ther* 2010; 31: 502-508.
71. Mirici-Cappa F, Gramenzi A, Santi V, Zambruni A, Di Micoli A, Frigerio M, Maraldi F, Di Nolfo MA, Del Poggio P, Benvegnù L, Rapaccini G, Farinati F, Zoli M, Borzio F, **Giannini EG**, Caturelli E, Bernardi M, Trevisani F; Italian Liver Cancer Group. Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. *Gut* 2010; 59: 387-396.
72. **Giannini EG**, Basso M, Bazzica M, Contini P, Marengo S, Savarino V, Picciotto A. Successful antiviral therapy determines a significant decrease in squamous cell carcinoma antigen-associated (SCCA) variants' serum levels in anti-HCV positive cirrhotic patients. *J Viral Hepat* 2010; 17: 563-568.
73. Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, Di Nolfo MA, Benvegnù L, Farinati F, Zoli M, **Giannini EG**, Borzio F, Caturelli E, Chiaramonte M, Bernardi M; Italian Liver Cancer (ITA.LI.CA) Group. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. *J Hepatol* 2010; 53: 291-297.
74. **Giannini EG**, Greco A, Marengo S, Andorno E, Valente U, Savarino V. Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease. *Clin Gastroenterol Hepatol* 2010; 10: 899-902.
75. Furnari M, Parodi A, Gemignani L, **Giannini EG**, Marengo S, Savarino E, Assandri L, Fazio V, Bonfanti D, Inferrera S, Savarino V. Clinical Trial: the association between rifaximin and partially hydrolyzed guar gum is more effective than rifaximin alone in eradicating SIBO. *Aliment Pharmacol Ther* 2010; 32: 1000-1006.
76. **Giannini EG**, Basso M, Savarino V, Picciotto A. Predictive factors for response to peginterferon-alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more. *Dig Dis Sci* 2010; 55: 3193-3199.
77. **Giannini EG**, Savarino V, Risso D, Di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA.) group. Relative decrease in the role played by hepatitis B virus infection in the aetiology of hepatocellular carcinoma during a 20-year period: a multicentre Italian study. *Liver Int* 2011; 31: 192-196.
78. Torre F, **Giannini EG**, Basso M, Fazio V, Savarino V, Picciotto A. Initial high dose of lamivudine delays the appearance of viral resistance in chronic hepatitis B patients. *J Gastrointest Liver Dis* 2011; 20: 47-50.

79. Agha A, Alsaudi D, Furnari M, Abdulhadi Ali MM, Al-Majadah SS, Savarino V, Inferrera S, **Giannini EG**. Efficacy of 48-hour post-operative antibiotics prophylaxis for patients undergoing percutaneous endoscopic gastrostomy tube in preventing site infection. *J Gastrointest Liver Dis* 2011; 20: 131-134.
80. Vitale A, Morales RR, Zanus G, Farinati F, Burra P, Angeli P, Frigo AC, Del Poggio P, Rapaccini G, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, **Giannini EG**, Caturelli E, Chiaramonte M, Trevisani F, Cillo U; Italian Liver Cancer group. Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. *Lancet Oncol* 2011; 12: 654-662.
81. Agha A, Abdulhadi MM, Marengo S, Bella A, Alsaudi D, El-Haddad A, Inferrera S, Savarino V, **Giannini EG**. Use of the platelet count/spleen diameter ratio for the noninvasive diagnosis of esophageal varices in patients with schistosomiasis. *Saudi J Gastroenterol* 2011; 17: 307-311.
82. Farinati F, Giacomini A, Vanin V, Sergio A, Burra P, Cillo U, Di Nolfo A, Del Poggio P, Benvegnù L, Zoli M, Borzio F, **Giannini EG**, Caturelli E, Cazzagon N, Rapaccini GL, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Liver transplantation for hepatocellular carcinoma in clinical practice: the lesson from a 20-year multicentre experience in Italy. *Eur J Gastroenterol Hepatol* 2012; 24: 195-202.
83. Santi V, Buccione D, Di Micoli A, Fatti G, Frigerio M, Farinati F, Del Poggio P, Rapaccini G, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, **Giannini EG**, Caturelli E, Chiaramonte M, Bernardi M, Trevisani F. The changing scenario of hepatocellular carcinoma over the last two decades in Italy. *J Hepatol* 2012; 56: 397-405.
84. Cucchetti A, Trevisani F, Cescon M, Ercolani G, Farinati F, Poggio PD, Rapaccini G, Nolfo MA, Benvegnù L, Zoli M, Borzio F, **Giannini EG**, Caturelli E, Chiaramonte M, Pinna AD; for the Italian Liver Cancer (ITA.LI.CA) Group. Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. *J Hepatol* 2012; 56: 1089-1096.
85. **Giannini EG**, Marengo S, Fazio V, Pieri G, Savarino V, Picciotto A. Peripheral blood cytopenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy. *Liver Int* 2012; 32: 1113-1119.
86. Furnari M, Savarino E, Bruzzone L, Moscatelli A, Gemignani L, **Giannini EG**, Zentilin P, Dulbecco P, Savarino V. Reassessment of the role of methane production between irritable bowel syndrome and functional constipation. *J Gastrointest Liver Dis* 2012; 21: 157-163.
87. Afdhal NH, **Giannini EG**, Tayyab G, Mohsin A, Lee JW, Andriulli A, Jeffers L, McHutchison J, Chen PJ, Han KH, Campbell F, Hyde D, Brainsky A, Theodore D, for the ELEVATE study group. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. *N Engl J Med* 2012; 367: 716-724.
88. **Giannini EG**, Marengo S, Borgonovo G, Savarino V, Farinati F, Del Poggio P, Rapaccini GL, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; for the Italian Liver Cancer (ITA.LI.CA) group. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. *Hepatology* 2012; 56: 1371-1379.

89. **Giannini EG**, Marengo S, Bruzzone L, Savarino V, Farinati F, Del Poggio P, Rapaccini GL, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F. Hepatocellular carcinoma in patients without cirrhosis in Italy. *Dig Liver Dis* 2013; 45: 164-169.
90. Agha A, AlSaudi D, Furnari M, Abdulhadi Ali MM, Chakik RM, AlSaudi I, Savarino V, **Giannini EG**. Feasibility of the cut-and-push method for removing large caliber, soft, percutaneous endoscopic gastrostomy devices. *Nutr Clin Pract* 2013; 28: 490-492.
91. Cazzagon N, Trevisani F, Maddalo G, Giacomini A, Vanin V, Pozzan C, Del Poggio P, Rapaccini GL, Di Nolfo AM, Benvegnù L, Zoli M, Borzio F, **Giannini EG**, Caturelli E, Chiaramonte M, Foschi FG, Cabibbo G, Felder M, Ciccarese F, Missale G, Svegliati Baroni G, Morisco F, Pecorelli A, Farinati F, the ITA.LI.CA Group. Rise and fall of HCV-related hepatocellular carcinoma in Italy: A long term survey from the Ita.Li.Ca centres. *Liver Int* 2013; 33: 1420-1427.
92. **Giannini EG**, Savarino V. Relationship between 13C-Aminopyrine Breath Test and the MELD score and its long-term prognostic use in patients with cirrhosis. *Dig Dis Sci* 2013; 58: 3024-3028.
93. **Giannini EG**, Savarino V, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F, for the Italian Liver Cancer (ITA.LI.CA) group. Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. *Liver Int* 2013; 33: 1594-1600.
94. Bolondi L, Cillo U, Colombo M, Craxì A, Farinati F, **Giannini EG**, Golfieri R, Levrero M, Pinna AD, Piscaglia F, Raimondo G, Trevisani F, Bruno R, Caraceni P, Ciancio A, Coco B, Fraquelli M, Rendina M, Squadrito G, Toniutto P. Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma. *Dig Liver Dis* 2013; 45: 712-723.
95. Agha A, Chakik RM, Abdulhadi Ali MM, AlSaudi D, Sammito G, **Giannini EG**. Peg-Interferon Alpha-2a and low-dose ribavirin for treatment of hepatitis C virus infection in patients with sickle cell anemia in Saudi Arabia. *Ann Saudi Med* 2013; 33: 610-613.
96. Afdhal NH, Dusheiko GM, **Giannini EG**, Chen PJ, Han KH, Mohsin A, Rodriguez-Torres M, Rugina S, Bakulin I, Lawitz E, Shiffman ML, Tayyab GUN, Poordad F, Kamel YM, Brainsky A, Geib J, Vasey SY, Patwardhan R, Campbell FM, Theodore D. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. *Gastroenterology* 2014; 146: 442-452.
97. Carr BI, Guerra V, **Giannini EG**, Farinati F, Ciccarese F, Ludovico Rapaccini G, Di Marco M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; for the Italian Liver Cancer (ITA.LI.CA) Group. Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype. *Semin Oncol* 2014; 41: 252-258.
98. **Giannini EG**, Sammito G, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Svegliati Baroni G, Virdone R, Trevisani F; for the Italian Liver Cancer (ITA.LI.CA) Group. Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use. *Cancer* 2014; 120: 2150-2157.
99. Carr BI, Pancoska P, **Giannini EG**, Farinati F, Ciccarese F, Ludovico Rapaccini G, Di Marco M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer



- (ITA.LI.CA) Group. Identification of two clinical hepatocellular carcinoma patient phenotypes from results of standard screening parameters. *Semin Oncol* 2014; 41: 406-414.
100. Cucchetti A, Trevisani F, Pecorelli A, Erroi V, Farinati F, Ciccarese F, Rapaccini GL, Marco MD, Caturelli E, **Giannini EG**, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Baroni GS, Virdone R, Bernardi M, Pinna AD; for the Italian Liver Cancer (ITA.LI.CA) group. Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. *J Hepatol* 2014; 61: 333-341.
101. Carr BI, Guerra V, **Giannini EG**, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani T for the Italian Liver Cancer (ITA.LI.CA) group. Significance of platelet and AFP levels and liver function parameters for HCC size and survival. *Int J Biol Markers* 2014; 29: e215-223.
102. Del Poggio P, Olmi S, Ciccarese F, Di Marco M, Rapaccini GL, Benvegnù L, Borzio F, Farinati F, Zoli M, **Giannini EG**, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Factors that affect efficacy of ultrasound surveillance for early-stage hepatocellular carcinoma in patients with cirrhosis. *Clin Gastroenterol Hepatol* 2014; 11: 1927-1933.
103. Carr BI, Guerra V, **Giannini EG**, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F. Low alpha-fetoprotein HCC and the role of GGTP. *Int J Biol Markers* 2014; 29: 395-402.
104. **Giannini EG**, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, Benvegnù L, Caturelli E, Zoli M, Borzio F, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Prognosis of untreated hepatocellular carcinoma. *Hepatology* 2015; 61: 184-190.
105. Biselli M, Conti F, Gramenzi A, Frigerio M, Cucchetti A, Fatti G, D'Angelo M, Dall'Agata M, **Giannini EG**, Farinati F, Ciccarese F, Andreone P, Bernardi M, Trevisani F. A new approach to the use of  $\alpha$ -fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. *Br J Cancer* 2015; 112: 69-76.
106. **Giannini EG**, Marengo S, Boni S, Beltrame A, Nicolini LA, Taramasso L, Feasi M, Grasso A, De Leo P, Percario G, Bartolacci V, Artioli S, Viscoli C, Cassola G, Testa R, Anselmo M, Riccio G, Savarino V, Picciotto A; for the Ligurian Hepatitis B Virus Study Group. Therapeutic management of chronic hepatitis B in clinical Practice: a region-wide survey. *J Clin Gastroenterol* 2015; 49: 228-234.
107. Farinati F, Vanin V, Giacomini A, Pozzan C, Cillo U, Vitale A, Nolfo AM, Poggio PD, Benvegnù L, Rapaccini G, Zoli M, Borzio F, **Giannini EG**, Caturelli E, Trevisani F; The Italian Liver Cancer (ITA.LI.CA) group. BCLC-B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. *Liver Int* 2015; 35: 223-231.
108. Vitale A, Burra P, Frigo AC, Trevisani F, Farinati F, Spolverato G, Volk M, **Giannini EG**, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Baroni GS, Virdone R, Cillo U; for the Italian Liver Cancer (ITA.LI.CA) group. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. *J Hepatol* 2015; 62: 617-624.

109. Nicolini LA, Taramasso L, Schiavetti I, **Giannini EG**, Beltrame A, Feasi M, Cassola G, Grasso A, Bartolacci V, Sticchi L, Picciotto A, Viscoli C; the Ligurian Hepatitis B Virus Study Group. Epidemiological and clinical features of hepatitis delta in HBsAg-positive patients by HIV status. *Antivir Ther* 2015; 20: 193-197.
110. **Giannini EG**, Afdhal NH, Sigal SH, Muir AJ, Reddy KR, Vijayaraghavan S, Elkashab M, Romero-Gomez M, Dusheiko GM, Iyengar M, Vasey SY, Campbell FM, Theodore D. Non-cirrhotic thrombocytopenic patients with hepatitis C virus: characteristics and outcome of antiviral therapy. *J Gastroenterol Hepatol* 2015; 30: 1301-1308.
111. Romano F, Ruggeri M, Coretti S, **Giannini EG**, Sacchini D, Annichiarico BE, Marchetti M, Rodeghiero F, Lidonnici D. Economic assessment of eltrombopag in the treatment of thrombocytopenia. *Expert Rev Pharmacoecon Outcomes Res* 2015; 15: 713-720.
112. Agha A, Furnari M, Chakik RM, Abdulhadi Ali MH, Alsaudi D, Bazeed M, Savarino V, **Giannini EG**. Hepatocellular carcinoma is the most frequent final diagnosis of focal liver lesions identified in a cross-sectional evaluation of patients with chronic liver disease in Saudi Arabia. *Journal of Cancer Research* 2015; Article ID 492782.
113. Vitale A, Burra P, **Giannini EG**, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Missale G, Gasbarrini A, Svegliati Baroni G, Virdone R, Spolverato G, Trevisani F for the Italian Liver Cancer (ITA.LI.CA) group. Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: a multicenter cohort study. *Liver Transpl* 2015; 21: 1250-1258.
114. Bruno S, Sewpaul P, Russo ML, Boccaccio V, Almasio PL, **Giannini EG**. 12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post-hoc analysis of eltrombopag studies. *Dig Liver Dis* 2015; 47: 864-868.
115. Romano F, Ruggeri M, Coretti S, **Giannini EG**, Sacchini D, Annichiarico BE, Marchetti M, Rodeghiero F, Lidonnici D. Economic assessment of eltrombopag in the treatment of thrombocytopenia in Italy. *Value in Health* 2015; 18: A626.
116. Bodini G, **Giannini EG**, Furnari M, Marabotto E, Baldissarro I, Del Nero L, Assandri L, Moscatelli A, Savarino V, Savarino E. Comparison of two different techniques to assess adalimumab trough levels in patients with Crohn's disease. *J Gastrointest Liver Dis* 2015; 24: 451-456.
117. **Giannini EG**, Moscatelli A, Pellegatta G, Vitale A, Farinati F, Ciccarese F, Piscaglia F, Rapaccini L, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Missale G, Foschi FG, Gasbarrini A, Svegliati Baroni G, Virdone R, Masotto A, Trevisani F, for the Italian Liver Cancer (ITA.LI.CA) group. Application of the intermediate stage sub-classification to patients with untreated hepatocellular carcinoma. *Am J Gastroenterol* 2016; 111: 70-77.
118. Bucci L, Garuti F, Camelli V, Lenzi B, Farinati F, **Giannini EG**, Ciccarese F, Fabio Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Maida M, Felder M, Morisco F, Gasbarrini G, Gemini S, Foschi FG, Missale M, Masotto A, Affronti A, Bernardi M, Trevisani F, for the Italian Liver Cancer (ITA.LI.CA) group. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatments and outcome. *Aliment Pharmacol Ther* 2016; 43: 385-399.
119. Cucchetti A, Trevisani F, Bucci L, Ravaioli M, Farinati F, **Giannini EG**, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Maida M, Felder M, Morisco F,

- Gasbarrini A, Gemini S, Foschi FG, Missale G, Masotto A, Affronti A, Bernardi M, Pinna AD for the Italian Liver Cancer (ITA.LI.CA) group. Years of life that could be saved from prevention of hepatocellular carcinoma. *Aliment Pharmacol Ther* 2016; 43: 814-824.
120. **Giannini EG**, Moscatelli A, Brunacci M, Zentilin P, Savarino V. Prognostic role of mean platelet volume in patients with cirrhosis. *Dig Liver Dis* 2016; 48: 409-413.
121. Grotzinger KM, Younossi ZM, **Giannini EG**, Chen PJ, Rendas-Baum R, Theodore D. Health-related quality of life in thrombocytopenic patients with chronic hepatitis C and cirrhosis in the ENABLE-1 and ENABLE-2 studies. *Health Qual Life Outcomes* 2016; 14: 49
122. Under the auspices of the Italian Association for the Study of Liver Diseases (AISF) and the Italian Society of Internal Medicine (SIMI). Andriulli A, Tripodi A, Angeli P, Senzolo M, Primignani M, **Giannini EG**, Riggio O, Colli A, Prati D, Sacerdoti D, Merkel C, Basili S, Ferro D, Villa E, Di Minno D, Caraceni P, Marzioni M, Mannucci PM, Violi F. Hemostatic balance in patients with liver cirrhosis: A report of a Consensus Conference. *Dig Liver Dis* 2016; 48: 455-467.
123. Farinati F, Vitale A, Spolverato G, Pawlik TM, Huo T, Lee YL, Frigo AC, Giacomini A, **Giannini EG**, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Biasini E, Foschi FG, Gasbarrini A, Svegliati Baroni G, Virdone R, Masotto A, Trevisani F, Cillo U. Development and validation of a new prognostic system for patients with hepatocellular carcinoma. *PLoS Med* 2016; 13: e1002006.
124. Bodini G, **Giannini EG**, Savarino V, Del Nero L, Pellegatta G, De Maria C, Baldissarro I, Savarino E. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease. *Scand J Gastroenterol* 2016; 51: 1081-6.
125. Carr BI, Guerra V, **Giannini EG**, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Masotto A, Trevisani F. An HCC aggressiveness index and blood GTP, bilirubin and platelet levels. *J Integr Oncol* 2016; 5: 172.
126. Carr BI, Guerra V, **Giannini EG**, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Masotto A, Trevisani F. A liver index and its relationship to indices of HCC aggressiveness. *J Integr Oncol* 2016;5: 178.
127. Bitzer M, Horger M, **Giannini EG**, Ganten TM, Wörns MA, Siveke JT, Dollinger MM, Gerken G, Scheulen ME, Wege H, Zagonel V, Cillo U, Trevisani F, Santoro A, Montesarchio V, Malek NP, Holzappel J, Herz T, Ammendola AS, Pegoraro S, Hauns B, Mais A, Lauer UM, Henning SW, Hentsch B. Resminostat in combination with sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER Study. *J Hepatol* 2016; 65: 280-288.
128. Petta S, Cabibbo G, Barbara M, Attardo S, Bucci L, Farinati F, **Giannini EG**, Tovoli F, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Colecchia A, Persico M, Boccaccio V, Craxì A, Bruno S, Trevisani F, Cammà C; Italian Liver Cancer (ITA.LI.CA) Group. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. *Aliment Pharmacol Ther* 2017; 45: 160-168.
129. Caldwell S, Intagliata N, Gatt A, Reuben A, Farias A, Lackner C, Eby C, Greenberg C, Jenne C, Leveille-Webster CR, Kleiner D, Rijken D, Valla D, Gabriel D, **Giannini E**, Villa E, Deangelis G,

Cortez-Pinto H, Wanless I, Gorham J, Luyendyk J, Garcia-Pagan JCC, Senzolo M, Magnussen M, Hoffman M, Englesbee M, Mendez-Sanchez N, Shah N, Intagliata N, Key N, Simioni P, Northup P, Rautou P-E, Chowdary P, Steadman R, Porte R, Sabri S, Lee S, Pelletier S, Caldwell S, Mallet S, Stravitz T, Lisman T, Ikura Y, Henry ZA The Coagulation in Liver Disease 2015 Group. Summary of the 6th international conference on coagulation in liver disease: Discussion, debate, deliberations. *Ann Hepatol* 2017; 16: 12-15.

130. Bucci L, Garuti F, Lenzi B, Pecorelli A, Farinati F, **Giannini EG**, Granito A, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cammà C, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Colecchia A, Bernardi M, Trevisani F, for the Italian Liver Cancer group. The evolutionary scenario of hepatocellular carcinoma in Italy: an update. *Liver Int* 2017; 37: 259-270.
131. Pecorelli A, Lenzi B, Gramenzi A, Garuti F, Farinati F, **Giannini EG**, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Felder M, Morisco F, Gasbarrini A, Baroni GS, Foschi FG, Biasini E, Masotto A, Virdone R, Bernardi M, Trevisani F; Italian LiverCancer (ITA.LI.CA) group. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. *Liver Int* 2017; 37: 423-33.
132. Bodini G, **Giannini EG**, De Maria C, Dulbecco P, Furnari M, Marabotto E, Savarino V, Savarino E. Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index. *Dig Liver Dis* 2017; 49: 175-180.
133. Burra P, Belli LS, Ginanni Corradini S, Volpes R, Marzioni M, **Giannini E**, Toniutto P. Common issues in the management of patients in the waiting list and after liver transplantation: HCV, HBV, alcoholic liver disease, immunosuppression. *Dig Liver Dis* 2017; 49: 241-253.
134. Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, **Giannini EG**, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A; ABACUS study group; AIFA team. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. *Lancet Gastroenterol Hepatol* 2017; 2: 427-434.
135. Cabibbo G, Petta S, Barbara M, Attardo S, Bucci L, Farinati F, **Giannini EG**, Negrini G, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Virdone R, Marra F, Mega A, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Colecchia A, Persico M, Craxì A, Trevisani F, Cammà C; Italian Liver Cancer (ITA.LI.CA) group. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. *J Hepatol* 2017; 67: 65-71.
136. Kondili LA, Gaeta GB, Brunetto MR, Di Leo A, Iannone A, Santantonio TA, Giammarino A, Raimondo G, Filomia R, Coppola C, Amoroso DC, Blanc P, Del Pin B, Chemello L, Cavalletto L, Morisco F, Donnarumma L, Rumi MG, Gasbarrini A, Siciliano M, Massari M, Corsini R, Coco B, Madonia S, Cannizzaro M, Zignego AL, Monti M, Russo FP, Zanetto A, Persico M, Masarone M, Villa E, Bernabucci V, Taliani G, Biliotti E, Chessa L, Pasetto MC, Andreone P, Margotti M,

- Brancaccio G, Ieluzzi D, Borgia G, Zappulo E, Calvaruso V, Petta S, Falzano L, Quaranta MG, Weimer LE, Rosato S, Vella S, **Giannini EG**. Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. *PLoS One* 2017; 12: e0185728.
137. **Giannini EG**, Bucci L, Garuti F, Brunacci M, Lenzi B, Valente M, Caturelli E, Cabibbo G, Piscaglia F, Virdone R, Felder M, Ciccarese F, Foschi FG, Sacco R, Baroni GS, Farinati F, Rapaccini GL, Olivani A, Gasbarrini A, Di Marco M, Morisco F, Zoli M, Masotto A, Borzio F, Benvegnù L, Marra F, Colecchia A, Nardone G, Bernardi M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. *Hepatology* 2018; 67: 1784-1796.
138. Bodini G, **Giannini EG**, Savarino V, Del Nero L, Lo Pumo S, Brunacci M, De Bortoli N, Jain A, Tolone S, Savarino E. Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease. *Dig Liver Dis* 2018; 50: 452-456.
139. Vitale A, Lai Q, Farinati F, Bucci L, **Giannini EG**, Napoli L, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Colecchia A, Bernardi M, Trevisani F, Pawlik TM; Italian Liver Cancer (ITA.LI.CA) group. Utility of tumor burden score to stratify prognosis of patients with hepatocellular cancer: results of 4759 cases from ITA.LI.CA study group. *J Gastrointest Surg* 2018; 22: 579-581.
140. **Giannini EG**, Coppo C, Romana C, Camerini GB, De Cian F, Scopinaro N, Papadia FS. Long-term follow-up study of liver-related outcome after bilio-pancreatic diversion in patients with initial, significant liver damage. *Dig Dis Sci* 2018; 63: 1946-1951.
141. Carbone M, Nardi A, Flack S, Carpino G, Varvaropoulou N, Gavrila C, Spicer A, Badrock J, Bernuzzi F, Cardinale V, Ainsworth HF, Heneghan MA, Thorburn D, Bathgate A, Jones R, Neuberger JM, Battezzati PM, Zuin M, Taylor-Robinson S, Donato MF, Kirby J, Mitchell-Thain R, Floreani A, Sampaziotis F, Muratori L, Alvaro D, Marzioni M, Miele L, Marra F, **Giannini E**, Gaudio E, Ronca V, Bonato G, Cristoferi L, Malinverno F, Gerussi A, Stocken DD, Cordell HJ, Hirschfield GM, Alexander GJ, Sandford RN, Jones DE, Invernizzi P, Mells GF; Italian PBC Study Group and the UK-PBC Consortium. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. *Lancet Gastroenterol Hepatol* 2018; 3: 626-634.
142. **Giannini EG**, Giambruno E, Brunacci M, Plaz Torres MC, Furnari M, Bodini G, Zentilin P, Savarino V. Low fibrinogen levels are associated with bleeding after varices ligation in thrombocytopenic cirrhotic patients. *Ann Hepatol* 2018; 17: 830-835.
143. Ascione A, De Luca M, Melazzini M, Montilla S, Trotta MP, Petta S, Puoti M, Sangiovanni V, Messina V, Bruno S, Izzi A, Villa E, Aghemo A, Zignego AL, Orlandini A, Fontanella L, Gasbarrini A, Marzioni M, **Giannini EG**, Craxì A; ABACUS Study Group. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. *Infection* 2018; 46: 607-615.
144. Vitale A, Farinati F, Noaro G, Burra P, Pawlik TM, Bucci L, **Giannini EG**, Faggiano C, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Virdone R, Marra F,

- Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Colecchia A, Fornari F, Marignani M, Vicari S, Bortolini E, Cozzolongo R, Grasso A, Aliberti C, Bernardi M, Frigo AC, Borzio M, Trevisani F, Cillo U; Italian Liver Cancer (ITA.LI.CA) group. Restaging patients with hepatocellular carcinoma before additional treatment decisions: a multicenter cohort study. *Hepatology* 2018; 68: 1232-1244.
145. Morisco F, Guarino M, Valvano MR, Auriemma F, Farinati F, **Giannini EG**, Ciccarese F, Tovoli F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Felder M, Benvegnù L, Gasbarrini A, Svegliati Baroni G, Foschi FG, Biasini E, Masotto A, Virdone R, Marra F, Caporaso N, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Metabolic disorders across hepatocellular carcinoma in Italy. *Liver Int* 2018; 38: 2028-2039.
146. Minutolo R, Aghemo A, Chirianni A, Fabrizi F, Gesualdo L, **Giannini EG**, Maggi P, Montinaro V, Paoletti E, Persico M, Perticone F, Petta S, Puoti M, Raimondo G, Rendina M, Zignego AL; Italian Society of Nephrology (SIN); Italian Association for the Study of the Liver (AISF); Italian Society of Infectious and Tropical Disease (SIMIT); Italian Society of Internal Medicine (SIMI). Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). *J Nephrol* 2018; 31: 685-712.
147. Minutolo R, Aghemo A, Chirianni A, Fabrizi F, Gesualdo L, **Giannini EG**, Maggi P, Montinaro V, Paoletti E, Persico M, Perticone F, Petta S, Puoti M, Raimondo G, Rendina M, Zignego AL; Italian Society of Nephrology (SIN); Italian Association for the Study of the Liver (AISF); Italian Society of Infectious and Tropical Disease (SIMIT); Italian Society of Internal Medicine (SIMI). Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). *Dig Liver Dis* 2018; 50: 1133-1152.
148. Carbone F, Bodini G, Brunacci M, Bonaventura A, Vecchiè A, Liberale L, Crespi M, Baldissarro I, Dallegri F, Savarino V, Montecucco F, **Giannini EG**. Reduction in TIMP-2 serum levels predicts remission of inflammatory bowel diseases. *Eur J Clin Invest* 2018; 48: e13002.
149. Minutolo R, Aghemo A, Chirianni A, Fabrizi F, Gesualdo L, **Giannini EG**, Maggi P, Montinaro V, Paoletti E, Persico M, Perticone F, Petta S, Puoti M, Raimondo G, Rendina M, Zignego AL; Italian Society of Nephrology (SIN); Italian Association for the Study of the Liver (AISF); Italian Society of Infectious and Tropical Disease (SIMIT); Italian Society of Internal Medicine (SIMI). Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). *Intern Emerg Med* 2018; 13: 1139-1166.
150. Carr BI, Giannelli G, Guerra V, **Giannini EG**, Farinati F, Rapaccini GL, Marco MD, Zoli M, Caturelli E, Masotto A, Virdone R, Sacco R, Trevisani F. Plasma cholesterol and lipoprotein levels in relation to tumor aggressiveness and survival in HCC patients. *Int J Biol Markers* 2018; 33: 423-431.

151. Pinato DJ, Allara E, Chen TY, Trevisani F, Minguez B, Zoli M, Harris M, Dalla Pria A, Merchante N, Platt H, Jain M, Caturelli E, Kikuchi L, Pineda J, Nelson M, Farinati F, Rapaccini GL, Aytaman A, Yin M, Tan CK, Bower M, **Giannini EG**, Bräu N; Liver Cancer in HIV and ITA.LI.CA Study Groups. Influence of HIV infection on the natural history of hepatocellular carcinoma: results from a global multicohort study. *J Clin Oncol* 2019; 37: 296-304.
152. Minutolo R, Aghemo A, Chirianni A, Fabrizi F, Gesualdo L, **Giannini EG**, Maggi P, Montinaro V, Paoletti E, Persico M, Perticone F, Petta S, Puoti M, Raimondo G, Rendina M, Zignego AL; Italian Society of Nephrology (SIN); Italian Association for the Study of the Liver (AISF); Italian Society of Infectious and Tropical Disease (SIMIT); Italian Society of Internal Medicine (SIMI). Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). *Infection* 2019; 47: 141-168.
153. **Giannini EG**, Crespi M, Demarzo M, Bodini G, Furnari M, Marabotto E, Torre F, Zentilin P, Savarino V. Improvement in HCV patients with advanced, compensated liver disease after SVR to antivirals. *Eur J Clin Invest* 2019; 49: e13056.
154. Furnari M, De Alessandri A, Cresta F, Haupt M, Bassi M, Calvi A, Haupt R, Bodini G, Ahmed I, Bagnasco F, **Giannini EG**, Casciaro R. The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled trial with rifaximin. *J Gastroenterol* 2019; 54: 261-270.
155. Ravaioli M, Odaldi F, Cucchetti A, Trevisani F, Piscaglia F, De Pace V, Bertuzzo VR, Neri F, Golfieri R, Capelli A, D'Errico A, Cescon M, Del Gaudio M, Fallani G, Siniscalchi A, Morelli MC, Ciccarese F, Di Marco M, Farinati F, **Giannini EG**, Pinna AD. Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria. *Sci Rep* 2019; 9: 3781.
156. Vitale A, Farinati F, Pawlik TM, Frigo AC, **Giannini EG**, Napoli L, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Colecchia A, Bernardi M, Trevisani F, Cillo U. The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: a multicenter cohort study. *Liver Int* 2019; 39: 1478-1489.
157. Bodini G, Demarzo MG, Saracco M, Coppo C, De Maria C, Baldissarro I, Savarino E, Savarino V, **Giannini EG**. High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease. *Scand J Gastroenterol* 2019; 54: 1220-1225.
158. Bodini G, Zanella C, Crespi M, Lo Pumo S, Demarzo G, Savarino E, Savarino V, **Giannini EG**. A randomized, 6-week trial of low-FODMAP diet in patients with Inflammatory Bowel Disease. *Nutrition* 2019; 67-68: 110542.
159. Petta S, Rini F, Calvaruso V, Cammà C, Ciminnisi S, Di Marco V, **Giannini EG**, Grimaudo S, Pipitone RM, Craxì A. Aminopyrine Breath Test predict liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy. *Liver Int* 2020; 40: 530-538.
160. Ferrarese A, Morelli MC, Carrai P, Milana M, Angelico M, Perricone G, Belli LS, Marrone G, Grieco A, Martini S, Manini MA, Fagioli S, Toniutto P, Galeota Lanza A, Bhoori S, S Petta,

- Giannini EG**, Burra P. Outcomes of liver transplant for adults with Wilson's Disease. *Liver Transpl* 2020; 26: 507-516.
161. **Gianni EG**, De Maria C, Crespi M, Demarzo MG, Fazio V, Grasso A, Torre F, Bodini G, Marabotto E, Furnari M. Course of oesophageal varices and performance of non-invasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease. *Eur J Clin Invest* 2020; 50:e13231.
162. Bodini G, Demarzo MG, Casagrande E, De Maria C, Kayali S, Ziola S, **Giannini EG**. Concerns related to COVID-19 pandemic among patients with Inflammatory Bowel Disease, and its influence on patients management. *Eur J Clin Invest* 2020; 50: e13233.
163. Bossen L, Rebora R, Bernuzzi F, Jepsen P, Gerussi A, Andreone P, Galli A, Terziroli B, Alvaro D, Labbadia G, Aloise C, Baiocchi L, **Giannini E**, Abenavoli L, Toniutto P, Marra F, Marzioni M, Niro G, Floreani A, Møller HJ, Valsecchi MG, Carbone M, Grønbaek H, Invernizzi P. Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis. *Liver Int* 2020; 40: 1408-1414.
164. Díaz-González Á, Sanduzzi-Zamparelli M, Gomes da Fonseca LL, Di Costanzo GG, Alves R, Iavarone M, Leal C, Sacco R, Matilla AM, Hernández-Guerra M, Aballay Soteras G, Wörns MA, Pinter M, Varela M, Ladekarl M, Chagas AL, Mínguez B, Arenas JI, Granito A, Sánchez-Torrijos Y, Rojas Á, Rodríguez de Lope C, Alvares-da-Silva MR, Pascual S, Rimassa L, Lledó JL, Huertas C, Sangro B, **Giannini EG**, Delgado M, Vergara M, Perelló C, Lue A, Sala M, Gallego A, Coll S, Hernández T, Piñero F, Pereira G, França A, Marín J, Anders M, Mello V, Lozano M, Nault JC, Menéndez J, García Juárez I, Bruix J, Reig M. International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis. *Liver Int* 2020; 40: 1467-1476.
165. **Giannini EG**, Crespi M, Djahandideh A, Demarzo MG, Moscatelli A, Bodini G, Furnari M, Marabotto E, Plaz Torres MC, Zentilin P, Savarino V. Appropriateness of proton pump inhibitors treatment in clinical practice: prospective evaluation in outpatients and perspective assessment of drug optimization. *Digest Liver Dis* 2020; 52: 862-868.
166. Sangiovanni A, Alimenti E, Gattai R, Filomia R, Parente E, Valenti L, Marzi L, Pellegatta G, Borgia G, Gambato M, Terreni N, Serio I, Belli L, Oliveri F, Maimone S, Brunacci M, D'Ambrosio R, Forzenigo LV, Russo FP, Rumi M, Barone M, Fracanzani AL, Raimondo G, **Giannini EG**, Brunetto MR, Villa E, Biganzoli E, Colombo M, Lampertico P. Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. *J Hepatol* 2020;73:593-602.
167. Ghisa M, Laserra G, Marabotto E, Ziola S, Tolone S, de Bortoli N, Frazzoni M, Mauro A, Penagini R, Savarino V, Barberio B, **Giannini EG**, Zentilin P, Gyawali CP, Savarino E. Achalasia and obstructive motor disorders are not uncommon in patients with eosinophilic esophagitis. *Clin Gastroenterol Hepatol* 2020 Aug 4:S1542-3565(20)31066-1. doi: 10.1016/j.cgh.2020.07.056
168. Furnari M, Eusebi LH, Savarino E, Petruzzellis C, Esposito G, Maida M, Ricciardiello L, Pecere S, Buda A, De Bona M, Spada C, Di Giulio E, Costamagna G, Boskoski I, **Giannini EG**; Young-ENDO-ITA Study Group. Effects of SARS-CoV2 emergency measures on high-risk lesions detection: a



multicentre cross-sectional study. *Gut* 2020 Sep 28:gutjnl-2020-323116. doi: 10.1136/gutjnl-2020-323116.

169. Campani C, Vitale A, Dragoni G, Arena U, Laffi G, Cillo U, **Giannini EG**, Tovoli F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Mega A, Guarino M, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Biasini E, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Farinati F, Trevisani F, Marra F. Time-varying mHAP III is the most accurate predictor of survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. *Liver Cancer* accepted for publication in November 2020
170. Monofocal hepatocellular carcinoma: how much does size matter? *Liver Int* accepted for publication in November 2020

## Reviews

1. **Giannini EG**, Testa R. <sup>13</sup>C-breath tests and liver fibrosis. *Eur Rev Med Pharmacol Sci* 2004; 8: 51-54.
2. Zentilin P, Dulbecco P, Savarino E, **Giannini E**, Savarino V. Combined multichannel intraluminal impedance and pH-metry: a novel technique to improve detection of gastro-oesophageal reflux: Literature review. *Dig Liver Dis* 2004; 36: 565-569.
3. **Giannini EG**, Testa T, Savarino V. Liver enzyme alteration: a guide for clinicians. *Canadian Medical Association Journal* 2005; 172; 367-379.
4. **Giannini EG**, Kane SV, Testa R, Savarino V. 5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for “best evidence”? *Dig Liver Dis* 2005; 37: 723-731.
5. **Giannini EG**, Mansi C, Dulbecco P, Savarino V. Role of partially hydrolysed guar gum in the treatment of irritable bowel syndrome. *Nutrition* 2006; 22: 334-342.
6. **Giannini EG**. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. *Aliment Pharmacol Ther* 2006; 23: 1055-1065.
7. **Giannini EG**, Savarino V. Thrombocytopenia in liver disease. *Curr Opin Hematol* 2008; 15: 473-480.
8. **Giannini EG**, Greco A, Savarino V. A review on the use of eltrombopag in patients with advanced liver disease. *Clinical Medicine Insights: Therapeutics*: <http://www.la-press.com/a-review-on-the-use-of-eltrombopag-in-patients-with-advanced-liver-dis-a1700>.
9. **Giannini EG**, Afdhal NH. Eltrombopag in patients with chronic liver disease. *Expert Opin Pharmacother* 2013; 14: 669-678.
10. **Giannini EG**, Cucchetti A, Erroi V, Garuti F, Odaldi F, Trevisani F. Surveillance for early diagnosis of HCC: how to do it at best. *World J Gastroenterol* 2013; 19: 8808-8821.
11. **Giannini EG**. Eltrombopag in patients with chronic hepatitis C and thrombocytopenia. *Future Virol* 2014; 9: 9-20.
12. Furnari M, Savarino V, **Giannini EG**. Use of liver breath tests to assess severity of nonalcoholic fatty liver disease. *Rev Recent Clin Trials* 2014; 9: 178-184.
13. Furnari M, de Bortoli N, Martinucci I, Bodini G, Revelli M, Marabotto E, Moscatelli A, Del Nero L, Savarino E, **Giannini EG**, Savarino V. Optimal management of constipation associated with irritable bowel syndrome. *Ther Clin Risk Manag* 2015; 11: 691-703.
14. **Giannini EG**, Peck-Radosavljevic M. Platelet dysfunction: status of thrombopoietin in thrombocytopenia associated with chronic liver failure. *Semin Thromb Hemost* 2015; 41: 455-461.
15. Furnari M, Iftikhar A, van Erpecum KJ, Savarino V, **Giannini EG**. Breath tests to assess alcoholic liver disease. *Rev Recent Clin Trials* 2016; 11: 185-190.
16. Vitale A, Peck-Radosavljevic M, **Giannini EG**, Vibert E, Sieghart W, van Poucke S, Pawlik T. Personalized treatment of patients with very early hepatocellular carcinoma. *J Hepatol* 2017; 66: 412-423.

17. Ponziani FR, Miele L, Tortora A, Furnari M, Bodini G, Pompili M, Gasbarrini A, **Giannini EG**. Treatment of early stage chronic Hepatitis C Virus infection. *Expert Rev Clin Pharmacol* 2018 11: 519-524.
18. Burra P, **Giannini EG**, Caraceni P, Ginanni Corradini S, Rendina M, Volpes R, Toniutto P. Specific issues concerning the management of patients on the waiting list and after liver transplantation: referral, difficult candidates, nutrition, living related liver transplants, hepatocellular carcinoma, new antivirals for HCV. *Liver Int* 2018; 38: 1338-1362.
19. Guarino M, Viganò L, Ponziani FR, **Giannini EG**, Lai Q, Morisco F; Special Interest Group on Hepatocellular carcinoma and new anti-HCV therapies of the Italian Association for the Study of the Liver. Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. *Dig Liver Dis* 2018; 50: 1105-1114.
20. Lai Q, Vitale A, Manzia TM, Foschi FG, Levi Sandri GB, Gambato M, Melandro F, Russo FP, Miele L, Viganò L, Burra P, **Giannini EG**; for the Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group. Platelets and hepatocellular cancer: bridging the bench to the clinics. *Cancers (Basel)* 2019 Oct 15;11(10) pii: E1568.
21. **Giannini EG**, for the Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group. Overview of immune checkpoint inhibitors therapy for hepatocellular carcinoma, and the ITA.LI.CA cohort derived estimate of amenability rate to immune checkpoint inhibitors in clinical practice. *Cancers (Basel)* 2019 Oct 30;11(11). pii: E1689
22. Plaz Torres MC, Aghemo A, Lleo A, Bodini G, Furnari M, Marabotto E, Miele L, **Giannini EG**. Mediterranean diet and NAFLD: what we know and questions that still need to be answered. *Nutrients* 2019; 11: E2971
23. Marabotto E, Ziola S, Savarino V, **Giannini EG**, Furnari, Bodini G, Zingone F, Ghisa M, Barberio B, Zentilin P, Savarino E. Vonoprazan fumarate for the treatment of gastric ulcers: a short review on emerging data. *Clin Experiment Gastroenterol* 2020: 13: 99-104.
24. Plaz Torres MC, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M, **Giannini EG**. Surveillance for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: universal or selective?". *Cancers* 2020; 12: 1422.
25. Plaz Torres MC, Bodini G, Furnari M, Marabotto E, Zentilin P, **Giannini EG**. Nuts and non-alcoholic fatty liver disease: are nuts safe for patients with fatty liver disease? *Nutrients* 2020; 12: E3363.
26. Savarino V, Marabotto E, Zentilin P, Demarzo MG, Pellegatta G, Frazzoni M, De Bortoli N, Tolone S, **Giannini EG**, Savarino E. Esophageal reflux hypersensitivity: Non-GERD or still GERD? *Dig Liver Dis*. 2020 Oct 21:S1590-8658(20)30932-4. doi: 10.1016/j.dld.2020.10.003.

## Editoriali

1. **Giannini EG.** Review: MRI is more sensitive but less specific than ultrasonography or spiral CT for diagnosis of hepatocellular carcinoma. *ACP Journal Club* 2006; 145: 21.
2. **Giannini EG, Savarino V.** Predictors of pathological severity in non-alcoholic fatty liver disease: Is East meeting West in the middle? *J Gastroenterol Hepatol* 2007; 22: 461-463.
3. **Giannini EG.** Primary prophylaxis for small esophageal varices PRO: cirrhotic patients with small esophageal varices should undergo primary prophylaxis. *Am J Gastroenterol* 2009; 104: 2132-2134.
4. **Giannini EG, Savarino V.** Further insights into the causes of thrombocytopenia in chronic hepatitis C. *J Gastrointest Liver Dis* 2010; 19: 357-358.
5. **Giannini EG, Savarino V.** Epidemiology of thrombocytopenia in chronic hepatitis C patients: more than meets the eye. *J Viral Hepat* 2011; 18: 8-10.
6. **Giannini EG.** Safety of cardiac surgery in cirrhotic patients: going to the heart of the matter. *Clin Gastroenterol Hepatol* 2012; 10: 350-351.
7. **Giannini EG, Erroi V, Trevisani F.** Effectiveness of  $\alpha$ -fetoprotein for hepatocellular carcinoma surveillance: the return of the living-dead? *Expert Rev Gastroenterol Hepatol* 2012; 6: 441-444.
8. **Giannini EG.** Thrombocytopenia in patients with chronic liver disease: what's in a name? *Dig Dis Sci* 2013; 58: 299-301.
9. **Giannini EG.** Platelet count manipulation and modification of global haemostasis tests in patients with chronic liver disease: almost there, almost there... *Liver Int* 2013; 33: 325-326.
10. **Giannini EG.** Editorial: a step forward in refining prognostication in patients with HIV-associated hepatocellular carcinoma. *Aliment Pharmacol Ther* 2018; 47: 133-134.
11. **Giannini EG, Aghemo A.** Micro-elimination of Hepatitis C Virus infection in  $\beta$ -thalassaemia major patients: positively moving towards the World Health Organisation 2030 eradication goal. *Dig Liver Dis* 2019; 51: 568-569.
12. **Giannini EG, Trevisani F.** Ramucirumab as a second-line treatment for hepatocellular carcinoma: REACHing out further to patients with elevated alpha-fetoprotein. *Hepatobiliary Surg Nutr* 2019;8: 515-518.
13. **Indolfi G, Giannini EG.** Hepatitis C virus therapy in children: No one should be left behind. *Liver Int* 2020; 40: 283-285.
14. **Giannini EG.** Improving prognosis of patients with very early hepatocellular carcinoma: how far are we going? *Dig Liver Dis* accepted for publication in November 2020

## Case Reports

1. **Giannini E**, Fasoli A, Botta F, Testa R. Wilson's Disease with concomitant  $\beta$  Thalassemia and Factor V Deficiency. *Ital J Gastroenterol Hepatol* 1998; 30: 633-635.
2. Marenco S, **Giannini EG**, Savarino V. Patent paraumbilical vein-induced hepatic encephalopathy. *Clin Gastroenterol Hepatol* 2010; 10: A28.
3. Del Nero L, Mazza F, Cittadini G, Savarino V, **Giannini EG**. "Starry liver": an unexpected diagnosis. *ACG Case Rep J* 2015; 2: 77-78.
4. Plaz Torres MC, Romana C, Coppo C, Zentilin P, Grillo F, Savarino V, **Giannini EG**. Hepatobiliary and pancreatic: A rare cause of portal hypertension. *J Gastroenterol Hepatol* 2016; 31: 11.
5. Del Nero L, Moscatelli A, Fazio V, Pellegatta G, Bongioanni F, Sambuceti G, Savarino V, **Giannini EG**. Positive positron emission tomography in a patient with esophageal leiomyoma. *Am J Gastroenterol* 2016; 111: 767.
6. Lo Pumo S, Cacciato V, De Maria C, **Giannini EG**. The hepatologist in the haematologist field: a rare cause of non-cirrhotic portal hypertension. *Ann Hematol Oncol* 2018; 51: 1190.
7. Crespi M, Demarzo MG, Brunacci M, Pellegatta G, Ferrando F, Ballestrero A, Grillo F, Savarino V, **Giannini EG**. Improvement in Waldenstrom's macroglobulinemia after successful treatment of HCV with direct-acting antivirals. *Ann Hepatol* 2018; 17: 1072-1077.
8. Caranci G, Cordano C, **Giannini E**, Bandini F. Acquired hepatocerebral degeneration in the absence of portosystemic shunting. *J Clin Neurol* 2019; 15:128-129.
9. De Maria C, Ghidotti I, Grillo F, **Giannini EG**. Successful DAAs treatment and global improvement in a cirrhotic patient with concomitant HCV infection and autoimmune hepatitis. *Dig Dis Sci* 2019; 64: 591-593.
10. Cacciato V, Casagrande E, Bodini G, Furnari M, Marabotto E, Grillo F, **Giannini EG**. Eradication of hepatitis C virus infection disclosing a previously hidden, underlying autoimmune hepatitis: Autoimmune hepatitis and HCV. *Ann Hepatol* 2020; 19: 222-225.

## Lettere

1. **Giannini E**, Botta F, Romagnoli P, Testa R. Oral or intravenous lidocaine administration to perform MEGX test. *Dig Dis Sci* 2000; 45: 1011-1012.
2. **Giannini E**, Fasoli A, Botta F, Romagnoli P, Malfatti F, Chiarbonello B, Testa R. Is there a role for multiple quantitative liver function tests? *Dig Liver Dis* 2000; 32: 644.
3. **Giannini E**, Testa R. Is aspartate aminotransferase enough? *Am J Gastroenterol* 2000; 95: 3687-3688.
4. **Giannini E**, Testa R. Chronic hepatitis C in different populations: similar patterns of ALT alteration characterize similar clinical subgroups. *Hepatology* 2001; 33: 313.
5. **Giannini E**, Risso D, Testa R. Transportability and reproducibility of the AST/ALT ratio in chronic hepatitis C patients. *Am J Gastroenterol* 2001; 96: 918-919.
6. **Giannini E**, Testa R. Persistently normal aminotransferase in chronic HCV infection: is it time to redefine parameters of "normality"? *Dig Liver Dis* 2001; 33: 202-203.
7. **Giannini E**, Barreca T, Testa R. Leptin in nonalcoholic steatohepatitis: is it one of the "hits"? *Am J Gastroenterol* 2001; 96: 2519-2520.
8. **Giannini E**, Ceppa P, Testa R. Steatosis in chronic hepatitis C: can weight reduction improve therapeutic efficacy? *J Hepatol* 2001; 35: 432-433.
9. **Giannini E**, Testa R. Surveillance for hepatocellular carcinoma in liver cirrhosis: have programmes improved because patients have? *Gut* 2002; 51: 456-457.
10. **Giannini E**, Testa R. Can changing counseling strategy change the picture of the chronic hepatitis C patient population? *Arch Intern Med* 2002; 162: 2497.
11. **Giannini E**, Botta F, Testa R. Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer. *Gastroenterology* 2003; 125: 993-994.
12. **Giannini E**, Testa R. Noninvasive diagnosis of fibrosis: The truth is rarely pure and never simple. *Hepatology* 2003; 35: 1312-1313.
13. **Giannini E**, Testa R. The metabolic syndrome: all criteria are equal, but some criteria are more equal than others. *Arch Intern Med* 2003; 163: 2787-2788.
14. **Giannini E**, Testa R. Non-invasive assessment of liver function: trying not to miss an opportunity. *Aliment Pharmacol Ther* 2004; 19: 827-828.
15. **Giannini EG**, Botta F, Testa R. Prediction of oesophageal varices with platelet count/spleen diameter ratio or platelets alone. *Gut* 2004; 53: 914-915.
16. **Giannini EG**, Testa R. Reply to Farinati et al.: classification of 'intermediate stage', untreated hepatocellular carcinoma patients: the neighbour's grass is not so green. *J Intern Med* 2004; 256: 531.
17. **Giannini EG**, Romagnoli P, Testa R. Eligibility criteria for antiviral therapy in HCV-positive patients: similar things to (almost) similar people. *Am J Gastroenterol* 2006; 101: 406-407.
18. **Giannini EG**, Savarino V. HCV and fat: something is missing. *J Hepatol* 2009; 50: 421-422.
19. **Giannini EG**, Savarino V. Blessed are those who have not seen and yet have believed. *Am J Gastroenterol* 2010; 105: 227-228.

20. **Giannini EG**, Savarino V, Risso D, Di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F for the Italian Liver Cancer (ITA.LI.CA.) group. TACE in Child-Pugh class B patients with HCC: between the devil and the deep blue sea. *Liver Int* 2010; 30: 923-924.
21. **Giannini EG**, Farinati F, Trevisani F. Alpha-fetoprotein in hepatocellular carcinoma surveillance: wake not the dead. *Hepatology* 2011; 54: 376-377.
22. Savarino E, Assandri L, **Giannini EG**, Savarino V. Small intestinal bacterial overgrowth and *Helicobacter pylori* – Can they be cause of thrombocytopenia in patients with chronic liver disease? *Am J Gastroenterol* 2011; 106: 1171-1172.
23. **Giannini EG**, Marengo S, Baldissarro E, Fazio V. Letter to the Editors: IL28B rs 12979860 C/T polymorphism in elderly chronic hepatitis C patients treated with pegylated-interferon and ribavirin. *Aliment Pharmacol Ther* 2011; 34: 398-400.
24. Abdulhadi–Ali MM, Alsaudi D, Agha A, Ibraheem–Alqahtani N, Furnari M, Savarino V, **Giannini EG**. Full-dose peginterferon alfa-2a and low-dose ribavirin treatment of genotypes 1 and 4 chronic hepatitis C patients with end-stage renal disease. *Clin Gastroenterol Hepatol* 2011; 9: 1004.
25. Farinati F, **Giannini E**, Trevisani F. TACE treatment in hepatocellular carcinoma: what should we do now? *J Hepatol* 2012; 57: 221-222.
26. **Giannini EG**, Savarino V. Comment to: Platelet count/spleen diameter ratio for non-invasive diagnosis of oesophageal varices: Is it useful in compensated cirrhosis? *Dig Liver Dis* 2012; 44: 965.
27. **Giannini EG**, Farinati F, Del Poggio P, Rapaccini GL, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F, for the Italian Liver Cancer (ITA.LI.CA) group. Ten-year outcome of radiofrequency thermal ablation for hepatocellular carcinoma: an Italian experience. *Am J Gastroenterol* 2012; 107: 1588-1589.
28. **Giannini EG**, Savarino V. Which anticoagulant drug should be used treat portal vein thrombosis in patients with chronic liver disease? *Clin Gastroenterol Hepatol* 2013; 11: 103.
29. **Giannini EG**, Trevisani F. Surveillance for hepatocellular carcinoma: Just do it! *Am J Gastroenterol* 2013; 108: 1013-1014.
30. **Giannini EG**, Farinati F, Trevisani F. Adequate interval for hepatocellular carcinoma surveillance. *Am J Gastroenterol* 2013; 108: 1174.
31. **Giannini EG**, Savarino V. Predicting post-transplant prognosis of patients with hepatocellular carcinoma: what lies beneath alpha-fetoprotein? *Liver Transpl* 2013; 19: 1166-1167.
32. **Giannini EG**, Savarino V. Platelet count and survival of compensated cirrhotic patients with small HCC treated with surgery. *Hepatology* 2014; 59: 1649.
33. **Giannini EG**, Cucchetti A, Vitale A. Prognostic prediction and identification of candidates to salvage liver transplantation in patients with early hepatocellular carcinoma. *Liver Transpl* 2014; 20: 1150-1151.
34. **Giannini EG**, Stravitz RT, Caldwell SH. Correction of hemostatic abnormalities and portal pressure variations in patients with cirrhosis. *Hepatology* 2014; 60: 1442.
35. **Giannini EG**, Trevisani F. Improving survival of cirrhotic patients with hepatocellular carcinoma through application of standard of care. *Hepatology* 2014; 60: 1446-1447.

36. **Giannini EG**, Trevisani F. Accuracy of alpha-fetoprotein for the detection of hepatocellular carcinoma: one more nail in the coffin. *Clin Gastroenterol Hepatol* 2014; 12: 2138-2139.
37. **Giannini EG**, Trevisani F. Screening for hepatocellular carcinoma in chronic liver disease. *Ann Intern Med* 2015; 162: 239-240.
38. Bodini G, **Giannini EG**, Savarino E, Savarino V. Adalimumab trough levels and response to biological treatment in patients with Inflammatory Bowel Disease: a useful cut-off in clinical practice. *Am J Gastroenterol* 2015; 110: 472-473.
39. **Giannini EG**, Stravitz RT, Caldwell SH. Portal vein thrombosis and chronic liver disease progression: the closer you look the more you see. *Hepatology* 2016; 63: 342-343.
40. **Giannini EG**, Savarino V. An independent validation of the mortality score for the short-term prognostic prediction in patients with chronic hepatitis C virus infection and advanced liver disease. *Gut* 2016; 65: 183-184.
41. Furnari M, Bodini G, **Giannini EG**, Savarino V. Letter: faecal volatile organic metabolites, promising biomarkers in inflammatory bowel disease. *Aliment Pharmacol Ther* 2016; 43: 1240-1241.
42. **Giannini EG**, Savarino V. Non-invasive assessment of varices needing treatment in patients with cirrhosis: no one should be left behind. *Hepatology* 2017; 65: 2131.
43. **Giannini EG**, Bodini G, Savarino V. A nodule, is a nodule, is a nodule: may alpha-fetoprotein make the difference? *Am J Gastroenterol* 2017; 112: 1340.
44. Marabotto E, Furnari M, Savarino V, **Giannini EG**, Savarino E. Letter: It is time to adopt new objective parameters to accurately identify patients with functional heartburn. *Aliment Pharmacol Ther* 2018; 48: 107-108.
45. **Giannini EG**, Bodini G, Furnari M, Marabotto E. NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis. *J Hepatol* 2018; 69: 972-973.
46. **Giannini EG**, Bodini G, Furnari M, Marabotto E. Bleeding after paracentesis in patients with decompensated cirrhosis and acute kidney injury: the perfect storm. *Liver Int* 2018; 38: 2101.
47. Crespi M, Ghidotti I, Bodini G, Furnari M, Marabotto E, **Giannini EG**. Harmonising proton pump inhibitors treatment in the specialist setting following the SIGE recommendations. *Dig Liver Dis* 2019; 51: 173-174.
48. **Giannini EG**, Bodini G, Furnari M, Marabotto E. A closer look at factors associated with bleeding in cirrhotic patients. *Am J Gastroenterol* 2019; 114: 364-365.
49. **Giannini EG**, Demarzo M, Bodini G. Reproducibility and transportability of the absence of incremental infectious adverse events in patients with higher anti-TNF drug levels. *Inflamm Bowel Dis* 2019; 25: e73.
50. **Giannini EG**, Crespi M, Demarzo M, Bodini G, Furnari M, Marabotto E, Torre F. Regression of fibrosis after DAAs treatment of patients with HCV cirrhosis: transposability to non-decompensated patients. *J Exp Clin Hepatol* 2019; 9: 546.
51. **Giannini EG**, Bodini G, Furnari M, Marabotto E. Hepatocellular carcinoma intermediate stage sub-classification systems: one, none, and one hundred thousand. *Liver Cancer* 2019; 8: 524-526.



52. **Giannini EG**, Bodini G, Marabotto E, Plaz Torres MC, Zentilin P, Furnari M. Risk factors for bleeding following oesophageal band ligation: providing further evidence to ameliorate clinical practice. *Dig Liver Dis* 2020; 52: 792-793.
53. **Giannini EG**, Bodini G, Marabotto E, Furnari M. Applicability of parameters for the non-invasive diagnosis of esophageal varices needing treatment to cured HCV patients. *Clin Infect Dis* 2020 Jul 13:ciaa969. doi: 10.1093/cid/ciaa969
54. **Giannini EG**, Bodini G, Furnari M, Marabotto E. Proactive measures aimed at improving appropriateness of use of proton pump inhibitors in clinical practice. *Clin Gastroenterol Hepatol* accepted for publication in November 2020
55. Marabotto E, Savarino E, De Bortoli N, **Giannini EG**. Refractoriness to treatment suggests that clinical evaluation should go beyond the diagnosis of reflux disease. *Clin Gastroenterol Hepatol* accepted for publication in November 2020
56. Marabotto E, Ziola S, Djahandideh Sheijani A, **Giannini EG**. COVID-19 and liver disease: not all evil comes to harm. *Liver Int* accepted for publication in November 2020

## Articoli collaborativi

1. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, Ascione A, Santantonio T, Piccinino F, Andreone P, Mangia A, Gaeta GB, Persico M, Fagioli S, Almasio PL, on behalf of the Italian Association of the Study of the Liver Disease (AISF)\*. Sustained virological response to interferon- $\alpha$  is associated with improved outcome in HCV-related cirrhosis: A retrospective study. *Hepatology* 2007; 45: 579-587.  
*\*(Ulteriori Principali Investigatori: Aghemo A, Amato A, Boccia S, Colloredo G, Cursaro C, De Tullio D, Di Marco V, De Luca M, Fasano M, **Giannini E**, Gios M, Grattagliano I, Morisco F, Picciotto A, Del Poggio P, Rossi S, Stanzione M, Santoro R, Saracco G, Mazzaro C).*
2. Stroffolini T, Almasio PL, Persico M, Bollani S, Benvegnù L, Di Costanzo G, Pastore G, Aghemo A, Stornaiuolo G, Mangia A, Andreone P, Stanzione M, Mazzella G, Saracco G, Del Poggio P, Bruno S; Italian Association of the Study of the Liver Disease (AISF)\*. Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis. *Am J Gastroenterol* 2008; 103: 1966-1972.  
*\*(Ulteriori Principali Investigatori: **Giannini E**, Morisco F, Picciotto A, Fagioli S, Mazzaro C).*
3. Morisco F, Stroffolini T, Medda E, Amoroso DC, Almasio PL, Villa E, Zuin M, Paris B, Stanzione M, Caporaso N; NADIR Study Group.\* Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study. *J Viral Hepat* 2010; 17: 427-434.  
*\*(Ulteriori collaboratori: Aceti A, Amaddeo G, Ancarani F, Arcuri P, Attili A, Bandiera F, Bellati G, Benigno R, Benini F, Bombardieri G, Bruno S, Capretti A, Carrara M, Cottone C, Cozzolongo R, Demelia L, Di Gaetano G, Esposito P, Fanelli G, Gaeta GB, **Giannini EG**, Giorgini A, Grieco A, Guadagnino V, Lanzini A, Lo Bello S, Lupo S, Maracci M, Marchi S, Martines D, Mazzella G, Miele L, Milan M, Milani S, Minoli G, Montalto G, Morrone A, Nosotti L, Paroli M, Pastore G, Persico M, Piccinino F, Pinzello GB, Pozzi M, Roffi L, Russello M, Russo M, Sagnelli E, Savarino V, Soccorsi F, Squadrito G, Tabone M, Tarsetti F, Tesini EM, Testa R, Tripi S, Gianfranca S, Vandelli C, Zignego AL).*
4. Rosina F, Tosti ME, Borghesio E, Masocco M, Mele A, Coppola C, Milella M, Borgia G, Andreone P, Koch M, Zignego AL, Romano M, Carrara M, Almasio PL, Azzola E, Nardone G, Benedetti A, Carosi G, Mazzotta F, Sagnelli E, Rizzetto M; for the AIFA Study Group; Italian Association for the Study of the Liver (AISF); Italian Society for Infectious and Tropical Diseases (SIMIT); Italian Association of Hospital Gastroenterologists (AIGO); Italian Society of Gastroenterology (SIGE).\* Pegylated interferon  $\alpha$  plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency. *Dig Liver Dis* 2014;46: 826-832.  
*\*(Ulteriori collaboratori: Mascolo MC, Cursaro C, Scuteri A, Ranieri J, Monti M, Bellentani S, Gasbarrini A, Pompili M, Puoti C, Bellis L, Regazzetti A, Maffezzini E, Pietrangelo A, Abbati G, Raimondo G, Scribano L, Martines D, Baroni GS, Faraci G, Schianchi S, Fornaciari G, Fabris P, Madonia S, Civitavecchia G, Pirisi M, Smirne C, Borghi A, Sardini C, Andreoletti M, Morisco F, Caporaso N, Fargion S, Fatta E, Masutti F, Bonaventura ME, Autolitano A, Russello M, Bellia A, Toniutto P, Bitetto D, Mecenate F, Pasulo L, Lucà MG, Picardi A, Vespasiani U, Grattagliano I,*

Palasciano G, Romagno D, Crespi C, Gianstefani A, Gobbo G, Monti V, Giannelli G, Napoli N, Nosotti, Raspanti A, Cuccorese, Colombo AE, Florida, Plattella MS, Cassano P, Gentile I, Blanc PL, Messina V, Bonfante S, Bellissima P, Toti M, Vecchiet J, Falasca K, Portelli V, De Stefano G, Pietromatera G, Viganò P, Re T, Andreoni M, Raineri G, Massari M, Grossi PA, Caputo S, Cassola G, Feasi M, Foti G, Kunkar A, Corti G, Baragli F, Caterini L, Migliorini D, Chiodera A, Calleri G, Spezia C, Baiguera C, Puoti M, Brancaccio G, Gaeta GB, Vento S, Di Biagio A, Nicolini L, Liberti A, Iannece MD, Contini C, Tacconi D, Caremani M, Almi P, Chimenti M, Cosco, Messeri D, Esperti FC, Paffetti A, Mastropietro C, Moretti A, Spagnolo AL, Lomonaco L, Calì A, Mandelli G, Spinzi GC, Framarin L, Berrutti M, Boccia S, Simone L, Pazzi P, Fornari F, Comparato G, Casetti T, Foschi FG, Bertin T, Salvagnini M, Samori A, Ferretti E, Casiraghi MA, Marin R, Ciancio A, Campo N, Testa R, Rocco A, Federico A, Loguercio C, Rizzo S, **Giannini EG**, Corbo M, Riegler G, Esposito P, Ricci GL).

5. Bruno S, Bollani S, Zignego AL, Pascasio JM, Magni C, Ciancio A, Caremani M, Mangia A, Marengo S, Piovesan S, Chemello L, Babudieri S, Moretti A, Gea F, Colletta C, Perez-Alvarez R, Fornis X, Larrubia JR, Arenas J, Crespo J, Calvaruso V, Ceccherini Silberstein F, Maisonneuve P, Craxì A, Calleja JL; Italian and Spanish (IAS)-BoC Study Group.\* Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. *J Viral Hepat* 2015; 22: 469-480.

\*(*Collaboratori*: Di Marco V, Monti M, Rizzardini G, Landonio S, Rizzetto M, Lapini L, Piazzolla V, Picciotto A, Alberti A, Cavaletto L, Koch M, Massari M, Muratori L, Cipriano V, Montineri A, Iacobello C, Fangazio S, Pirisi M, Colombo A, Bellati G, Mazzotta F, Pierotti P, Traverso A, Serviddio G, Russello M, Santantonio T, Drenaggi D, Marchionne E, Zuin M, Delliponti M, Farina F, Andreone P, Scuteri A, Galli M, **Giannini E**, Nerli A, Carbonai S, Coppola N, Montalbano M, Portelli V, Di Biagio A, Nicolini L, Mastroianni C, Madonia S, Licata A, Montalto G, Giannitrapani L, Mondelli M, Pellicelli A, Toniutto P, Borgia G, Gentile I, De Luca M, Di Costanzo G, Corti G, Cento V, Sousa M, Delgado M, De la Revilla J, Navarro J, Barcena R, Romero-Gomez M, Fernandez-Rodriguez C, Narvaez I, Erdozain J, Molina E, Fernandez I, Cuenca B, Planas R, Garcia-Samaniego J, Ladero J, Gonzalez J, Serra M, Castellote I, Sola R, Anton T, Ryan I, Gonzalez F, Martinez E, Portu J.)

6. Intagliata NM, Argo CK, Stine JG, Lisman T, Caldwell SH, Violi F; faculty of the 7th International Coagulation in Liver Disease Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease\*: Proceedings of the 7th International Coagulation in Liver Disease Conference. *Thromb Haemost* 2018; 118: 1491-1506.

\*(*Collaborators*: Angelico M, Argo C, Basili S, Bechmann L, Bernal W, Büller H, Caldwell S, Garcia-Pagan JC, **Giannini E**, Greenberg C, Intagliata N, Jenne C, Lee S, Lisman T, Luyendyk J, Magnusson M, Maitland H, Mallett S, Mendez-Sanchez N, Munoz S, Northup P, Raparelli V, Rautou PE, Reuben A, Riggio O, Senzolo M, Shah N, Simioni P, Stanworth S, Stine J, Thornburg B, Valla D, Villa E, Violi F).

## Capitoli di libri

1. Dulbecco P, **Giannini EG**, Savarino V. Prevenzione del danno gastrointestinale: quale alternativa ai FANS? In: Fiorucci S, Morelli A. FANS e COXIB. Prevenzione e Clinica degli Eventi Avversi Gastrointestinali, Cardiovascolari e Renali. (2006. pp. 137-151).
2. Testa R, **Giannini EG**. Malattie epatiche congenite. In: Coordinamento Nazionale dei Docenti Universitari di Gastroenterologia. Manuale di Gastroenterologia Unigastro (2007-2009. pp 341-349).
3. Demelia L, **Giannini EG**. Malattie epatiche congenite. In: Coordinamento Nazionale dei Docenti Universitari di Gastroenterologia. Manuale di Gastroenterologia Unigastro (2010-2012. pp 305-315).
4. **Giannini EG**. Management of varices. In: "Managing the complications of cirrhosis, A practical approach" A. Zaman Editor. Slack Inc. Publisher. pp. 29-60, 2011.
5. **Giannini EG**, Riggio O. Encefalopatia. In: Coordinamento Nazionale dei Docenti Universitari di Gastroenterologia. Manuale di Gastroenterologia (2013-2015. pp 76-79).
6. **Giannini EG**, Galli A. Neoplasie epatocellulari e vascolari. In: Coordinamento Nazionale dei Docenti Universitari di Gastroenterologia. Manuale di Gastroenterologia (2016-2019. pp 221-228).
7. **Giannini EG**, Galli A. Neoplasie epatocellulari e vascolari. In: Coordinamento Nazionale dei Docenti Universitari di Gastroenterologia. Manuale di Gastroenterologia (2019-2022. pp 279-288).
8. **Giannini EG**, Galli A. Hepatocellular and vascular tumours. In: Coordinamento Nazionale dei Docenti Universitari di Gastroenterologia. Digestive Diseases (2019-2022. pp 267-276).